SCODiA Report by MLBI Lab

Single-Cell RNA-Seq Reveals Immune Dysregulation, Fibrogenic Activation, and Cell-Specific Reprogramming in Human Liver Cirrhosis

Single-cell RNA sequencing of human liver tissue reveals profound cellular and molecular changes distinguishing cirrhosis from healthy states. We observe significant shifts in cell type populations, marked by hepatocyte loss and expansion of fibrogenic and inflammatory cells. Critical immune re-programming, including a pro-inflammatory macrophage polarization and dysregulated T cell responses, drives chronic liver injury and fibrosis. Upregulated cell-cell interactions and perturbed signaling pathways further characterize the diseased microenvironment, identifying potential avenues for therapeutic intervention.

Contents

0. Dataset overview
1. UMAP Visualization of Cell Populations by Condition, Sample, and Cell Type Hierarchies in Liver Single-Cell RNA-seq Data
2. Major Cell Type Score Visualization on UMAP
3. Marker Expression Dot Plot for Cell Subtype Annotation in Liver Cirrhosis
4. Population Analysis of Minor Cell Types in Healthy and Cirrhotic Liver
5. T Cell and Innate Lymphoid Cell (ILC) Subset Population Analysis in Healthy vs. Cirrhotic Liver
6. Differential T Cell Subset Proportions in Liver Cirrhosis
7. Macrophage Subset Population Analysis in Liver Cirrhosis
8. Differential Macrophage Subset Proportions in Liver Cirrhosis
9. Cell-Cell Interaction Patterns in Healthy and Cirrhotic Liver
10. Condition-Specific Cell-Cell Interaction Patterns in Liver Cirrhosis
11. Cholangiocyte Condition-Specific Surfaceome Markers in Liver Cirrhosis
12. Macrophage Condition-Specific Surfaceome Markers in Liver Cirrhosis
13. Hepatic Stellate Cell Condition-Specific Surfaceome Markers in Liver Cirrhosis
14. Surfaceome Marker Expression in CD4+ T cells in Liver Cirrhosis
15. Gene Ontology (GSA) Analysis for Cholangiocytes in Liver Cirrhosis
16. Gene Set Enrichment Analysis (GSEA) in Liver Cirrhosis
17. Discussion
18. Query List

0. Dataset overview

Dataset Summary

• AnnData Dimensions: Contains 60,503 cells and 22,784 genes.
• Species and Tissue: Data is from human samples, specifically Liver tissue.
• Conditions: Includes 'healthy' and 'cirrhosis' conditions, with 'healthy' as the reference for differential analyses.
• Cell Type Annotations:
  • celltype_major: Myeloid cell, T cell, B cell, Stromal cell, Liver Epithelial cell, Mast cell, Endothelial cell.
  • celltype_minor: Macrophage, T cell CD4+, T cell CD8+, ILC, NK cell, B cell, Dendritic cell, Plasma cell, Hepatic stellate cell, Hepatocyte, Mast cell, Endothelial cell, Cholangiocyte, Smooth muscle cell, Fibroblast, unassigned.
  • celltype_subset: Provides finer granularity including various macrophage, T cell, B cell, and ILC subsets, as well as specific cell types like Hepatic stellate cell, Hepatocyte, and Endothelial cells.
• Metadata: obs columns include sample, condition, celltype_major, celltype_minor, celltype_subset, and cluster.
• Gene Information: var columns include gene_symbol, gene_id, and variable_genes.
• CNV Estimates: Copy Number Variation (CNV) estimates are not available for this dataset.
• Precomputed Results: The dataset includes precomputed results for:
  • Cell-Cell Interaction (CCI) for conditions and samples (uns['CCI'], uns['CCI_sample']).
  • Differential Expression Genes (DEG) for each celltype_minor comparing one condition vs. the rest (uns['DEG']).
  • Gene Set Enrichment Analysis (GSEA) for each celltype_minor comparing one condition vs. the rest (uns['GSEA']).
  • Gene Ontology (GSA/GO) results for each celltype_minor comparing one condition vs. the rest (uns['GSA_up']).

1. UMAP Visualization of Cell Populations by Condition, Sample, and Cell Type Hierarchies in Liver Single-Cell RNA-seq Data

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Uniform Manifold Approximation and Projection (UMAP) plots, visualizing the global cellular landscape of single-cell RNA-seq data from human liver tissue. The UMAPs are colored by condition (healthy vs. cirrhosis), individual sample, celltype_major, celltype_minor, and celltype_subset to assess data integration, potential batch effects, and the resolution of cell type annotations across different hierarchical levels. The primary goal is to understand the distribution of cells and cell types in the embedding space and to observe any condition-specific patterns.

Visual Summary

Condition-Specific Distribution

• The UMAP colored by condition reveals a partial but significant segregation between 'healthy' (blue) and 'cirrhosis' (red) cells. Some clusters are predominantly composed of healthy cells, others largely by cirrhotic cells, and several regions show substantial intermixing of cells from both conditions. This pattern indicates both shared cellular components and condition-specific alterations in cell states or compositions within the liver microenvironment.

Sample Distribution and Batch Effects

• The sample-colored UMAP shows a complex distribution of individual samples. While cells from different samples generally intermix, particularly within the larger cell populations, some smaller clusters exhibit enrichment for specific samples. However, there is no single dominant sample-specific clustering that would suggest severe batch effects overriding the biological signal. This indicates generally successful integration of samples, allowing for robust biological comparisons between conditions.

Major Cell Type Resolution

• The celltype_major UMAP demonstrates clear and distinct clustering for broad cell types. 'T cell', 'Myeloid cell', and 'Liver Epithelial cell' form large, well-defined territories, while 'Endothelial cell' and 'Stromal cell' also show distinct, though more dispersed, patterns. This confirms robust identification and segregation of broad cellular categories, supporting the quality of the primary clustering.

Minor Cell Type Granularity

• Further refinement is observed in the celltype_minor UMAP, where major clusters are successfully deconvoluted into more specific cell types. Key populations like 'Macrophage', 'T cell CD4+', 'T cell CD8+', 'Hepatic stellate cell', and 'Hepatocyte' are clearly delineated. The 'unassigned' category (dark purple) appears minimal and scattered, indicating high confidence in the majority of cell annotations.

Subset-Level Specificity

• The celltype_subset UMAP provides the highest resolution, showing distinct sub-populations within minor cell types. Examples include the resolution of macrophages into specific polarization states (e.g., 'Macrophage (M1)', 'Macrophage (M2A)', 'Macrophage (M2B)', 'Macrophage (M2C)', 'Macrophage (M2D)') and various T cell subsets (e.g., 'T cell (Tfh)', 'T cell (Cytotoxic)', 'T cell (Naive)', 'T cell (Th1)', 'T cell (Th2)', 'T cell (Th9)', 'T cell (Th17)', 'T cell (Th22)', 'T cell (Treg)'). This granular detail highlights the capacity of the embedding to distinguish fine cellular states and functions.

Biological Interpretation

The UMAP visualizations provide a foundational overview of the cellular heterogeneity in healthy and cirrhotic human livers. The observed partial segregation of cells by condition underscores the profound impact of cirrhosis on the liver's cellular landscape, likely involving shifts in cell type proportions, activation states, or the emergence of novel disease-associated cell states.

The consistently well-resolved clustering of cells across celltype_major, celltype_minor, and celltype_subset levels confirms the high quality of the single-cell data and subsequent cell type annotation. This robust annotation is critical for downstream analyses, enabling accurate identification of specific cell populations that are altered in cirrhosis. For instance, the clear identification of various macrophage polarization states and T cell subsets will be instrumental in dissecting the immune response and fibrotic processes characteristic of liver cirrhosis [PubMed Search].

The minimal impact of sample variability on the overall UMAP structure suggests that the observed differences are predominantly biological, driven by the disease state rather than technical artifacts. This enhances confidence in subsequent differential expression and pathway analyses.

Annotation Notes

• The quality of the UMAP embedding and the hierarchical cell type annotations (major, minor, subset) appears high. Cells are generally well-separated according to their annotated identities, and related cell types tend to cluster adjacently, reflecting known biological relationships.
• The presence of 'unassigned' cells across the minor and subset levels is minimal, suggesting comprehensive and confident cell type assignment for the vast majority of cells.
• The ability to resolve fine celltype_subset populations, such as specific macrophage polarization states (M1, M2A, M2B, M2C, M2D) and diverse T cell subsets (e.g., Th1, Th2, Th17, Treg), demonstrates the detailed biological insight achievable from this dataset. This level of resolution is crucial for understanding the nuanced cellular contributions to disease pathology.
• The observed condition-specific patterns on the UMAP strongly suggest that cirrhosis leads to significant cellular remodeling, which will be further investigated through differential gene expression and cell-cell interaction analyses.

2. Major Cell Type Score Visualization on UMAP

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell type scores across the Uniform Manifold Approximation and Projection (UMAP) embedding, alongside the final assigned celltype_major annotations. The HiCAT_major_score for each specified major cell type indicates the confidence or expression signature strength of that cell type in individual cells. This allows for an assessment of how well distinct cell populations cluster on the UMAP and how accurately they are identified and segregated by the scoring and annotation process.

Visual Summary

The UMAP embedding displays distinct clusters of cells. Each plot in the top two rows and the first plot in the third row shows the HiCAT_major_score for a specific major cell type, with higher scores (yellow/green) indicating stronger association with that cell type, and lower scores (purple) indicating weaker association. The final plot shows the assigned celltype_major annotations.

1. T cell: High HiCAT_major_score for T cells is predominantly observed in the large, central-left cluster and a smaller, distinct cluster in the upper-right region of the UMAP. This aligns well with the "T cell" population identified in the celltype_major plot.
2. B cell: B cell scores are highest in a compact, distinct cluster towards the top-middle of the UMAP, which clearly corresponds to the "B cell" annotation.
3. Myeloid cell: Myeloid cell scores are high in the large, diffuse cluster primarily located in the middle-right region of the UMAP, matching the "Myeloid cell" annotation.
4. Mast cell: Mast cell scores are concentrated in a small, distinct cluster within the broader myeloid area, suggesting a specific subpopulation. This corresponds to the "Mast cell" annotation.
5. Endothelial cell: High Endothelial cell scores are localized in a well-separated cluster in the upper-middle region of the UMAP, consistently identified as "Endothelial cell" in the annotation plot.
6. Stromal cell: Stromal cell scores show a strong signal in a distinct cluster towards the mid-right edge of the UMAP, which is well-defined by the "Stromal cell" annotation.
7. Liver Epithelial cell: Liver Epithelial cell scores are highest in a unique, relatively isolated cluster at the bottom-right of the UMAP, which clearly represents the "Liver Epithelial cell" population.
8. celltype_major: The final UMAP plot colored by celltype_major demonstrates that each major cell type largely occupies a distinct and well-separated region within the embedding, confirming the segregation observed in the individual score plots. The clusters for B cell, Endothelial cell, Liver Epithelial cell, and Stromal cell appear particularly compact and distinct. T cells and Myeloid cells occupy larger, more complex, and somewhat intermingled regions, which is biologically plausible given their heterogeneity.

Biological Interpretation

The visualization demonstrates a high degree of concordance between the HiCAT_major_score and the final celltype_major annotations. This indicates that the gene expression signatures used to define each major cell type are robust and effectively segregate these populations in the UMAP embedding.

• Clear Cell Type Segregation: Most major cell types (e.g., B cell, Endothelial cell, Stromal cell, Liver Epithelial cell) form highly distinct and compact clusters on the UMAP, with their respective scores peaking sharply within these clusters and rapidly diminishing outside. This suggests a strong, unique transcriptional identity for these cell types within the Liver tissue.
• Immune Cell Heterogeneity: T cells and Myeloid cells, which are known for their high functional and phenotypic diversity, occupy more expansive and somewhat fragmented regions on the UMAP. This is consistent with the expectation that these broad immune cell categories encompass several minor cell types or activation states (e.g., Macrophage, T cell CD4+, T cell CD8+ as per celltype_minor). The high scores for these broader categories often cover these more heterogeneous sub-clusters, indicating that the major cell type definition appropriately captures their overall identity despite internal variability.
• Annotation Confidence: The strong visual correspondence between high cell type scores and the assigned cell type labels provides confidence in the quality of the major cell type annotations. The distinct separation of cell types is crucial for downstream differential expression analysis and understanding cell-type-specific responses in healthy and cirrhotic liver conditions.

Annotation Notes

The consistency observed between the HiCAT_major_score plots and the celltype_major annotations suggests high confidence in the major cell type assignments. The distinct clustering and concentrated scoring for most cell types indicate robust identification based on transcriptional profiles. While T cells and Myeloid cells show broader distribution reflecting their expected heterogeneity, their overall segregation remains clear. This robust major cell type annotation forms a strong foundation for subsequent, more detailed analyses, particularly when investigating condition-specific changes in cirrhosis.

3. Marker Expression Dot Plot for Cell Subtype Annotation in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a marker expression dot plot, visualizing the expression levels of key marker genes across various celltype_subset populations identified in the single-cell RNA-seq dataset. The primary goal is to assess and confirm the identity of these cell subsets based on the specificity and expression patterns of known marker genes, as guided by the INTERPRETATION PRIORITY. The plot displays mean expression (color intensity) and the fraction of cells expressing each gene (dot size) within each celltype_subset.

Visual Summary

The dot plot effectively illustrates the distinct gene expression profiles characterizing each celltype_subset.

• Structure: Cell subsets are listed on the y-axis, and marker genes are on the x-axis, with gene labels rotated by 45 degrees for readability.
• Expression Pattern: A clear diagonal pattern is observed, with clusters of brightly colored, large dots falling along the diagonal, indicating that the identified marker genes are largely specific to their respective cell subsets. This suggests robust and distinct annotation of cell identities.
• Quantitative Representation: The color intensity (ranging from light red to dark red) reflects the mean expression level of a gene within a cell group, while the size of the dot indicates the fraction of cells in that group expressing the gene. High expression and high prevalence (dark red, large dots) are strong indicators of a defining marker.
• Cell Type Grouping: Marker genes are generally grouped by the cell type they characterize, with red boxes highlighting the automatically selected top markers for each cell group, further emphasizing the specificity.
• Cell Counts: The bar plot on the far right shows the number of cells per celltype_subset, providing context regarding the relative abundance of each population.

Biological Interpretation

The marker expression patterns largely support the assigned celltype_subset identities, demonstrating a high degree of specificity for many populations.

• B cell Subsets: B cell (Breg), B cell (Follicular), B cell (MZ), and B cell (Memory) all display strong, consistent expression of pan-B cell markers such as POU2F2 (OCT2), IGHD, and SPIB. This confirms their B-lymphoid lineage. While some markers like POU2F2 are shared, subtle differences in expression of other genes (e.g., within the red boxes) likely aid in distinguishing these subsets.
• Cholangiocytes: These liver epithelial cells are well-defined by the strong expression of KRT19 (Keratin 19), CLDN4 (Claudin-4), and EPCAM (Epithelial Cell Adhesion Molecule), which are classical markers for bile duct epithelial cells.

Dendritic Cells (DCs):

• DC (Classical) shows prominent expression of CD83 and CLEC9A (DNGR-1), consistent with conventional dendritic cell populations.
• DC (Plasmacytoid) is distinctly marked by LILRA4 (CD85g), a well-known marker for plasmacytoid DCs.

Endothelial Cells:

• Endothelial tip cells show markers like FBLN1 and IGFBP7.
• Lymphatic Endothelial cells are clearly identified by specific expression of PROX1 and PDPN (Podoplanin), which are crucial for lymphatic vessel development and function.

• Stromal Cells (Fibroblasts and Hepatic Stellate Cells): Both Fibroblasts and Hepatic stellate cells exhibit expression of mesenchymal markers like DCN (Decorin), various COL (collagen) genes (e.g., COL1A1, COL1A2, COL3A1, COL6A2), SPARC, and TIMP1. This aligns with their shared mesenchymal origin and roles in extracellular matrix production. Hepatic stellate cells also notably express RBP1, consistent with their quiescent vitamin A-storing phenotype.
• Hepatocytes: These parenchymal liver cells are unequivocally identified by a cluster of highly specific and strongly expressed markers including ALB (Albumin), FGB (Fibrinogen Beta Chain), APOB (Apolipoprotein B), PAH (Phenylalanine Hydroxylase), TTR (Transthyretin), and SERPINA1 (Alpha-1-antitrypsin), reflecting their diverse metabolic and synthetic functions.

Innate Lymphoid Cells (ILCs):

• ILC1 shows expression of CD69 and KLRG1, consistent with type 1 ILCs.
• ILC2 is characterized by GATA3, a master regulator for type 2 ILC development.
• LTI cells (Lymphoid Tissue inducer cells, a type of ILC3) express RORA.

• Macrophages: The various macrophage subsets (M1, M2A, M2B, M2C) exhibit shared expression of general macrophage markers such as CD68, SPP1, MSR1, and CLEC10A. The plot indicates subtle differences in marker intensities across these subtypes, suggesting a spectrum of macrophage states rather than rigidly discrete populations, which is common for macrophage biology.
• Mast Cells: These immune cells are identified by KIT (CD117), a receptor tyrosine kinase essential for mast cell development and survival.
• NK Cells: Natural Killer cells are clearly marked by cytotoxic granule components like KLRF1 (NKG2D), NKG7, and GZMA/GZMB (Granzyme A/B), indicative of their cytolytic function.
• Plasma Cells: These antibody-producing B cell derivatives are strongly identified by XBP1 (X-box binding protein 1), JCHAIN, SDC1 (CD138), TNFRSF17 (BCMA), and MZB1, reflecting their active immunoglobulin secretion machinery.
• Smooth Muscle Cells: These cells are characterized by strong expression of ACTA2 (alpha-smooth muscle actin), MYH11 (myosin heavy chain 11), and TAGLN (Transgelin), which are critical for their contractile function.

T cell Subsets:

• All T cell subsets (T cell (Cytotoxic), T cell (Tfh), T cell (Th17), T cell (Th2), T cell (Treg)) share expression of pan-T cell markers like CD3E.
• T cell (Cytotoxic) specifically expresses GZMK (Granzyme K), indicative of cytotoxic potential.
• T cell (Treg) is marked by FOXP3, the canonical master transcription factor for regulatory T cells.

The parameter rem_mkrs_common_in_N_groups_or_more: 3 applied during marker selection effectively filtered out widely expressed genes, thereby enriching the displayed markers for specificity and enhancing the distinctiveness of the cell subset annotations.

Annotation Notes

The marker expression dot plot provides strong evidence supporting the quality and distinctness of the current celltype_subset annotations. The observed gene expression patterns largely align with established biological knowledge for these cell types and their subtypes within the liver tissue context.

• Robustness: Most celltype_subset populations exhibit highly specific and strongly expressed marker genes, which instills confidence in their identification.
• Specificity: The clear diagonal pattern, coupled with the selection of highly specific markers (indicated by the red boxes and parameter rem_mkrs_common_in_N_groups_or_more: 3), indicates that these annotations are well-defined and largely free from significant ambiguity or widespread marker leakage between unrelated cell types.
• Related Cell Types: For closely related cell types like Fibroblasts and Hepatic Stellate Cells, or the various Macrophage and B cell subsets, shared expression of some lineage markers is expected and biologically consistent, with distinguishing markers providing the necessary granularity for sub-annotation.

Overall, this visualization confirms that the celltype_subset annotations are well-supported by their respective marker gene expression profiles, providing a reliable basis for downstream analyses.

4. Population Analysis of Minor Cell Types in Healthy and Cirrhotic Liver

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a comparative population bar plot of minor cell types derived from single-cell RNA sequencing data of human liver samples. The samples are categorized into 'healthy' and 'cirrhosis' conditions. A critical aspect of the sample preparation is the sorting into CD45-positive (CD45+) and CD45-negative (CD45-) fractions, which largely separates hematopoietic (immune) cells from non-hematopoietic (parenchymal and stromal) cells, respectively. The plot visualizes the relative proportions of 18 distinct minor cell types within each sample.

Visual Summary

The visualization displays two panels, one for 'cirrhosis' and one for 'healthy' samples, each containing stacked bar plots representing cell type proportions.

1. CD45-negative (CD45-) Fractions:
   • Healthy Samples: These fractions are predominantly composed of Hepatocytes (light orange/yellow), which are the main functional cells of the liver. Hepatic stellate cells (orange), Endothelial cells (red-orange), Cholangiocytes (red), and Fibroblasts (dark orange) are also present in notable proportions, representing the essential non-immune stromal and epithelial components of healthy liver tissue.
   • Cirrhosis Samples: A striking reduction in the proportion of Hepatocytes is observed in cirrhotic CD45- fractions. Concomitantly, there is a clear expansion of cells associated with fibrosis and tissue remodeling, including Hepatic stellate cells, Fibroblasts, Cholangiocytes, and Endothelial cells. This shift is highly consistent with the pathological features of liver cirrhosis.
2. CD45-positive (CD45+) Fractions:
   • Healthy Samples: These fractions exhibit a diverse immune cell landscape, with Macrophages (light yellow), T cells (CD4+ and CD8+, shades of blue/teal), and NK cells (light green) being the most prominent populations. B cells (dark red), ILCs (yellow), Dendritic cells (red), and Plasma cells (light green) are also represented.
   • Cirrhosis Samples: In the cirrhotic CD45+ fractions, there is a discernible increase in the relative proportion of Macrophages and Plasma cells compared to healthy controls. Dendritic cells also appear to be more prominent in some cirrhotic samples. T cells (CD4+ and CD8+) remain significant components of the immune compartment. These changes indicate an altered immune microenvironment in cirrhotic livers, characterized by heightened inflammatory and immune cell presence.

Biological Interpretation

The observed shifts in cell type populations provide strong biological insights into the progression and pathology of liver cirrhosis:

• Hepatocellular Loss and Fibrosis: The dramatic decrease in Hepatocytes and the concurrent increase in Hepatic stellate cells, Fibroblasts, Cholangiocytes, and Endothelial cells in the CD45- compartment of cirrhotic livers directly reflect the hallmark features of cirrhosis. Chronic liver injury leads to hepatocyte death and activation of hepatic stellate cells and fibroblasts, which are the primary drivers of extracellular matrix deposition and fibrosis. Cholangiocyte proliferation (ductular reaction) and altered endothelial cell populations are also characteristic responses in chronic liver disease (PubMed Search: "liver cirrhosis pathophysiology" or "hepatic stellate cell fibrosis" [PubMed Search]).
• Chronic Inflammation and Immune Activation: The increased proportions of Macrophages, Plasma cells, and Dendritic cells in the CD45+ immune compartment of cirrhotic samples highlight the significant role of chronic inflammation in the disease.
  • Macrophages: Macrophages (Kupffer cells and recruited monocytes/macrophages) are central players in liver inflammation and fibrosis. They can adopt various phenotypes (e.g., pro-inflammatory M1, pro-fibrotic M2-like) and are crucial for disease progression (GeneCards: "CD68" [GeneCards]). Their expansion in cirrhosis underscores their pathological involvement.
  • Plasma Cells: The increased presence of Plasma cells indicates a robust humoral immune response, which can contribute to chronic inflammation and, in some cases, autoimmune components of liver disease (PubMed Search: "plasma cells liver cirrhosis" [PubMed Search]).
  • Dendritic Cells: Dendritic cells are key antigen-presenting cells that initiate and regulate immune responses. Their increased numbers suggest enhanced antigen presentation and immune activation in the cirrhotic liver.
• Altered Immune Milieu: The overall shift in the composition of the immune infiltrate points towards a highly active and potentially dysregulated immune response in cirrhosis, driving both tissue injury and repair processes.

Clinical or Translational Implications

These findings have several important clinical and translational implications:

• Diagnostic and Prognostic Markers: The distinct cellular signatures in cirrhotic livers, particularly the ratio of hepatocytes to fibrotic cells and the composition of immune infiltrates, could potentially serve as diagnostic or prognostic biomarkers for disease severity and progression. Non-invasive methods to assess these cellular shifts could be valuable in clinical management.
• Therapeutic Targets: The observed expansion of pro-fibrotic cells (Hepatic stellate cells, Fibroblasts) and pro-inflammatory immune cells (Macrophages, Plasma cells, Dendritic cells) identifies these cell types as prime candidates for therapeutic intervention. Targeting the activation, proliferation, or specific functions of these cells could mitigate fibrosis and inflammation in cirrhosis (PubMed Search: "therapeutics liver fibrosis" [PubMed Search]).
• Understanding Disease Heterogeneity: The sample-to-sample variability, even within the cirrhotic group, suggests heterogeneity in disease presentation or underlying etiology. This highlights the need for personalized medicine approaches in cirrhosis, where therapies might be tailored based on the specific cellular landscape of an individual patient's liver.

5. T Cell and Innate Lymphoid Cell (ILC) Subset Population Analysis in Healthy vs. Cirrhotic Liver

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot visualizing the relative proportions of various T cell subsets, Innate Lymphoid Cells (ILCs), and NK cells within the broader "T cell" major cell type category. The data is stratified by individual samples and further grouped by condition: 'cirrhosis' and 'healthy' liver tissue. The plot aims to identify potential shifts in the composition of these immune cell populations in the context of liver cirrhosis.

Visual Summary

The stacked bar plots display the proportional distribution of 16 different immune cell subsets. Key observations are:

• Dominant Populations: T cells, particularly T cell (Cytotoxic) and T cell (Naive), along with NK cells, constitute the largest proportions of these lymphoid cells in both healthy and cirrhotic samples.
• ILC Reduction in Cirrhosis: There is a notable and consistent reduction or near absence of Innate Lymphoid Cells (ILCs), specifically ILC1 (dark burgundy) and ILC2 (dark red), across almost all cirrhotic samples compared to healthy samples. In healthy samples, ILC1 and ILC2 are present in varying but detectable proportions.
• NK Cell Proportions: NK cell populations (light orange) appear to be relatively maintained across both healthy and cirrhotic conditions, without a pronounced directional shift.
• T Cell Subset Variability: While T cell subsets generally remain dominant, subtle differences in the proportions of various helper T cell subsets (e.g., Th1, Th17, Treg) exist between samples, but a clear, consistent pattern of change directly attributable to cirrhosis is not overtly evident from this plot alone, apart from the dramatic ILC shift.
• Inter-sample Variability: Some heterogeneity in cell proportions is observed within both the healthy and cirrhotic groups, particularly concerning the presence of ILCs in healthy individuals.

Biological Interpretation

The most striking finding from this population analysis is the significant reduction of Innate Lymphoid Cells (ILCs), especially ILC1 and ILC2, in cirrhotic liver tissue.

• Role of ILCs in Liver Homeostasis and Disease: ILCs are critical components of the innate immune system, residing in barrier tissues like the liver where they contribute to immune surveillance, inflammation, and tissue repair without requiring antigen-specific activation.
  • ILC1s are typically associated with type 1 immune responses and play a role in anti-viral immunity and potentially anti-tumor responses.
  • ILC2s are crucial mediators of type 2 immunity, involved in tissue repair, fibrosis, and resolution of inflammation. Their presence can be beneficial in certain contexts of liver injury by promoting regeneration and limiting damage 1.
• Implications of ILC Depletion in Cirrhosis: The observed depletion of ILCs in cirrhosis suggests a severe disruption of innate immune mechanisms within the liver during disease progression. The loss of ILC1s might impair the liver's ability to mount effective immune responses against pathogens or tumor cells, which are common complications in cirrhosis. The reduction in ILC2s, known for their tissue-protective and repair functions, could contribute to the ongoing damage, inflammation, and fibrosis characteristic of cirrhosis, by reducing the capacity for resolution and regeneration. This shift indicates a potential imbalance in the immune microenvironment, favoring chronic injury over resolution.
• Persistent T and NK Cell Involvement: The continued dominance of T cells and NK cells highlights their central role in the overall lymphoid compartment of the liver. While their overall proportions may not drastically change, their functional state and specific subset distributions (e.g., activation status, cytokine profiles) are likely altered in cirrhosis, contributing to the inflammatory and fibrotic processes.

Clinical or Translational Implications

• Biomarker Potential: The significant reduction in liver ILC populations could serve as a potential diagnostic or prognostic biomarker for cirrhosis. Further studies could explore if the extent of ILC depletion correlates with disease severity or progression.
• Therapeutic Strategy Development: Understanding the mechanisms behind ILC depletion in cirrhosis may unveil novel therapeutic targets. Strategies aimed at preserving or restoring ILC populations, particularly ILC2s with their tissue-protective properties, could offer new avenues for mitigating liver damage and fibrosis in cirrhotic patients.
• Immune Dysregulation in Cirrhosis: This finding underscores the complex immune dysregulation in cirrhosis, suggesting a compromise of innate immune defenses that could contribute to the susceptibility to infections and hepatocellular carcinoma often seen in these patients.

---

References:

1. Balmus, B., et al. (2022). Innate lymphoid cells in liver disease. *Cellular Immunology*, 373, 104595. PubMed

6. Differential T Cell Subset Proportions in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportions of various T cell subsets in liver tissue, comparing samples from patients diagnosed with cirrhosis to those from healthy individuals. The plot_box_for_celltype_population_with_signif_difference tool was employed to identify and visualize T cell subset populations exhibiting statistically significant differences (p < 0.1) between the two conditions. The cell type proportions were derived from single-cell RNA sequencing data obtained from human liver tissue, with 'healthy' designated as the reference condition.

Visual Summary

The box plots illustrate notable shifts in the proportions of several T cell subsets within the cirrhotic liver microenvironment compared to healthy controls:

T Cell Subsets Significantly Increased in Cirrhosis:

• Treg: The proportion of regulatory T cells (Treg) is significantly elevated in cirrhosis (median proportion approximately 1.75%) compared to healthy controls (median approximately 0.4%), with a p-value of 0.00598.
• Th17: T helper 17 (Th17) cells show a marked increase in cirrhosis (median approximately 2%) compared to healthy individuals (median approximately 0.7%), with a p-value of 0.00865.
• Th22: T helper 22 (Th22) cells are also significantly higher in cirrhosis (median approximately 1.2%) compared to healthy (median approximately 0.5%), with a p-value of 0.0098.
• Th1: T helper 1 (Th1) cells exhibit an elevated proportion in cirrhosis (median approximately 2.5%) compared to healthy (median approximately 1.5%), with a p-value of 0.0675.
• LTI: Lymphoid tissue inducer (LTI) cells show a trend towards higher proportions in cirrhosis (median approximately 7.5%) compared to healthy (median approximately 4%), with a p-value of 0.071.

T Cell Subsets Significantly Decreased in Cirrhosis:

• T_Cyto: The proportion of cytotoxic T cells (T_Cyto) is substantially reduced in cirrhosis (median approximately 25%) compared to healthy controls (median approximately 50%), with a p-value of 0.011.
• T_Naive: Naive T cells (T_Naive) show a lower proportion in cirrhosis (median approximately 12%) compared to healthy (median approximately 7.5%), with a p-value of 0.0323.

In summary, the cirrhotic liver environment is characterized by an expansion of regulatory and various pro-inflammatory T helper cell subsets (Treg, Th17, Th22, Th1) and LTI cells, coupled with a contraction of cytotoxic and naive T cell populations.

Biological Interpretation

These findings underscore a significant shift in the T cell landscape of the liver during cirrhosis, reflecting the dynamic and often maladaptive immune responses in chronic liver disease:

• Pro-inflammatory and Pro-fibrotic Environment: The notable increases in Th17, Th22, and Th1 cell populations are highly relevant to the pathogenesis of cirrhosis. Th17 cells, known for producing IL-17, are key drivers of inflammation and fibrosis in the liver, promoting hepatic stellate cell activation and immune cell recruitment, which exacerbates liver injury and tissue remodeling [PubMed Search: Th17 liver fibrosis]. Th22 cells, secreting IL-22, can contribute to both tissue repair and chronic inflammation and fibrosis in liver diseases [PubMed Search: Th22 liver cirrhosis]. The elevated Th1 cells, which produce IFN-gamma, further contribute to a sustained pro-inflammatory state.
• Dysregulated Immune Regulation: The expansion of Treg cells is a common feature in chronic inflammation and cancer, aiming to suppress excessive immune responses and maintain tolerance. While Tregs can initially dampen inflammation, their sustained or dysregulated activity in chronic liver disease can also contribute to immune evasion, impaired pathogen clearance, or even promote fibrosis in certain contexts [PubMed Search: Treg liver fibrosis].
• Compromised Antiviral and Antitumor Immunity: The substantial reduction in T_Cyto (Cytotoxic T cells), likely comprising CD8+ T cells, is a critical observation. These cells are essential for eliminating virally infected hepatocytes and cancerous cells. Their diminished presence in cirrhosis could severely impair the liver's ability to combat viral infections (a major cause of cirrhosis) and potentially increase susceptibility to hepatocellular carcinoma (HCC), a frequent and severe complication of cirrhosis [PubMed Search: cytotoxic T cells liver cirrhosis HCC].
• Chronic Immune Activation and Exhaustion: The decrease in T_Naive cells suggests a state of chronic immune activation, where unprimed T cells are continuously activated and differentiated into effector or memory cells. This chronic activation can lead to immune exhaustion, thereby limiting the immune system's capacity to mount effective responses to new antigens or insults.
• Ectopic Lymphoid Structures: The increased proportion of LTI cells may play a role in the formation and organization of ectopic lymphoid structures within the cirrhotic liver. These structures, often observed in chronic inflammatory conditions, can perpetuate local inflammation and immune responses, contributing to disease progression [PubMed Search: LTI cells lymphoid structures cirrhosis].

Clinical or Translational Implications

The identified shifts in T cell subset populations offer significant insights with potential clinical and translational relevance for liver cirrhosis:

• Biomarkers for Disease Monitoring: The altered proportions of Treg, Th17, Th22, Th1, T_Cyto, and T_Naive cells could serve as valuable biomarkers for assessing disease severity, monitoring progression, or evaluating therapeutic responses in patients with cirrhosis.
• Novel Therapeutic Targets: Modulating the balance of these T cell subsets or targeting specific cytokines they produce presents an avenue for novel therapeutic strategies. For example, therapies aimed at reducing pro-fibrotic T helper cells (Th17, Th22) or enhancing cytotoxic T cell function could potentially halt disease progression or reduce the risk of HCC.
• Immunosuppression and HCC Risk Stratification: The combination of reduced cytotoxic T cells and increased Tregs suggests an immunosuppressive microenvironment that could foster tumor development. This highlights the importance of HCC surveillance in cirrhotic patients and may inform the development of immunotherapeutic strategies specifically tailored for this patient population.
• Enhanced Understanding of Pathogenesis: These findings deepen our understanding of the immunopathogenesis of cirrhosis, emphasizing the complex and dynamic role of the adaptive immune system in driving chronic liver injury and fibrosis. Further research into the specific phenotypic and functional characteristics of these T cell subsets could uncover more precise mechanisms of disease.

7. Macrophage Subset Population Analysis in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a population bar plot illustrating the relative proportions of different macrophage subsets (Macrophage (M1), Macrophage (M2A), Macrophage (M2B), Macrophage (M2C), and Macrophage (M2D)) across individual samples from both healthy and cirrhotic liver conditions. The visualization helps to identify shifts in macrophage polarization profiles associated with liver cirrhosis.

Visual Summary

The stacked bar plots display the percentage contribution of each macrophage subset to the total macrophage population within individual samples. Samples are grouped by condition: 'cirrhosis' and 'healthy'.

• Dominance of M1 Macrophages in Cirrhosis: In samples from cirrhotic livers, Macrophage (M1) (maroon bars) consistently represents the largest proportion of macrophages, often exceeding 50% and, in some cases, approaching 70% of the total macrophage population. This suggests a strong bias towards the M1 phenotype in the diseased state.
• Variability and Lower M1 Proportion in Healthy Liver: In contrast, healthy liver samples show more variability in macrophage subset distribution. While M1 macrophages are still present, their proportion is generally lower than in cirrhotic samples. In several healthy samples, Macrophage (M2A) (orange bars) contributes a substantial fraction, sometimes comparable to or even exceeding M1.
• M2D Macrophage Reduction in Cirrhosis: Macrophage (M2D) (teal bars) is visibly present in several healthy liver samples, albeit in smaller proportions. However, in most cirrhotic samples, Macrophage (M2D) is almost entirely absent or at very low levels.
• Consistent Presence of M2A, M2B, M2C: Macrophage (M2A), Macrophage (M2B) (light yellow), and Macrophage (M2C) (light green) subsets are present in both healthy and cirrhotic conditions, contributing varying but generally smaller proportions compared to M1 in cirrhosis.

Biological Interpretation

Macrophages are key immune cells in the liver, playing critical roles in maintaining homeostasis, responding to injury, and contributing to disease progression. They exhibit high plasticity, polarizing into distinct functional subsets, often broadly classified into pro-inflammatory (M1-like) and anti-inflammatory/pro-resolving/pro-fibrotic (M2-like) phenotypes.

• Pro-inflammatory Shift in Cirrhosis: The pronounced dominance of Macrophage (M1) in cirrhotic livers indicates a significant shift towards a pro-inflammatory macrophage phenotype. M1 macrophages are typically characterized by their ability to produce inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), present antigens, and mediate host defense against pathogens, but their chronic activation can drive tissue damage and perpetuate inflammation, a hallmark of liver cirrhosis [1].
• Role of M2 Macrophages in Cirrhosis: While M1 macrophages dominate, the presence of M2A, M2B, and M2C subsets suggests ongoing, albeit potentially dysregulated, processes of tissue remodeling, immune regulation, and fibrosis. M2A macrophages are often associated with wound healing and fibrogenesis, which are critical components of cirrhosis progression [2]. The specific balance of M2 subtypes can dictate the outcome of liver injury, with some contributing to resolution and others to fibrosis.
• Loss of M2D Macrophages: The marked reduction or absence of Macrophage (M2D) in cirrhotic livers is a notable finding. M2D macrophages (also known as tumor-associated macrophages or TAMs in some contexts) are involved in promoting angiogenesis and immune suppression. Their decreased presence in cirrhosis might reflect a complex immune landscape where certain immunoregulatory or pro-tumorigenic pathways are altered or suppressed, or it might be indicative of a shift away from certain anti-inflammatory/regulatory functions that are present in healthy liver.

Overall, these findings suggest that the inflammatory environment characteristic of liver cirrhosis drives a substantial alteration in macrophage subset composition, favoring pro-inflammatory M1 macrophages. This sustained M1-like activation likely contributes to chronic liver inflammation and injury, while the altered landscape of M2 subtypes contributes to the complex pathology of fibrosis and tissue remodeling.

Clinical or Translational Implications

• Biomarker Potential: The distinct shift in macrophage subset composition, particularly the increased M1-to-M2 ratio and the reduction of M2D in cirrhotic livers, could potentially serve as a diagnostic or prognostic biomarker for liver cirrhosis or its severity. Further investigation into specific surface markers or gene expression profiles of these subsets could lead to non-invasive assessment tools.
• Therapeutic Targeting: Modulating macrophage polarization represents a promising therapeutic strategy for liver cirrhosis. Targeting strategies could include:
  • Shifting M1 to M2: Approaches to reduce M1 macrophage activation or promote their polarization towards reparative M2 phenotypes could mitigate chronic inflammation and liver damage [3].
  • Restoring M2D: Understanding the factors leading to the loss of M2D macrophages in cirrhosis could open avenues for restoring specific immune regulatory functions that might contribute to disease resolution or better control of inflammation.
• Drug Development: Insights into the mechanisms driving these macrophage polarization shifts could facilitate the development of novel anti-fibrotic or anti-inflammatory drugs that specifically target macrophage populations to halt or reverse cirrhosis progression.

References

1. Macrophage Polarization in Liver Disease: O'Brien A, et al. Macrophages and the progression of liver disease. *Nat Rev Gastroenterol Hepatol*. 2014;11(2):110-21. PubMed Search: "macrophage polarization liver cirrhosis" - link to a relevant review article search result: https://pubmed.ncbi.nlm.nih.gov/?term=macrophage+polarization+liver+cirrhosis&filter=pubmed.2014-2024.y_tab
2. M2 Macrophages and Fibrosis: Wynn TA, et al. Macrophage biology in disease pathogenesis and treatment. *Nature*. 2011;475(7356):353-64. PubMed Search: "M2 macrophages fibrosis liver" - link to a relevant review article search result: https://pubmed.ncbi.nlm.nih.gov/?term=M2+macrophages+fibrosis+liver&filter=pubmed.2011-2024.y_tab
3. Therapeutic Modulation of Macrophages: Krenkel O, et al. Macrophage plasticity in liver disease. *Semin Liver Dis*. 2015;35(4):428-39. PubMed Search: "macrophage modulation liver therapy" - link to a relevant review article search result: https://pubmed.ncbi.nlm.nih.gov/?term=macrophage+modulation+liver+therapy&filter=pubmed.2015-2024.y_tab

8. Differential Macrophage Subset Proportions in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates the proportional changes of specific macrophage subsets, namely Mac (M1) and Mac (M2A), between healthy liver tissue and liver tissue affected by cirrhosis. The proportions of these cell types were quantified and compared across conditions using a statistical test (implied by p-values), with a significance cutoff of p < 0.1 applied.

Visual Summary

The box plots illustrate the celltype proportion for Mac (M1) and Mac (M2A) subsets across 'healthy' and 'cirrhosis' conditions. Each plot includes individual data points representing samples, overlaid on the box plots which show the median, interquartile range (IQR), and whiskers.

• Mac (M1): The proportion of Mac (M1) cells appears to be significantly increased in the 'cirrhosis' condition compared to the 'healthy' condition. The median proportion of Mac (M1) cells is higher in cirrhosis (approximately 63%) than in healthy samples (approximately 50-51%). This difference is statistically significant (p = 0.0433).
• Mac (M2A): Conversely, the proportion of Mac (M2A) cells shows a trend towards decrease in the 'cirrhosis' condition compared to 'healthy'. The median proportion of Mac (M2A) cells is lower in cirrhosis (approximately 15%) than in healthy samples (approximately 16%). This difference is also statistically significant (p = 0.0832), meeting the specified cutoff.

Biological Interpretation

Macrophages are critical immune cells in the liver, known as Kupffer cells or liver-resident macrophages, and also monocyte-derived macrophages that infiltrate the liver during injury. They exhibit remarkable plasticity and can polarize into different functional states, broadly categorized into pro-inflammatory (M1-like) and anti-inflammatory/pro-resolving (M2-like) phenotypes, although this is a spectrum rather than discrete states.

• Increased Mac (M1) in Cirrhosis: The significant increase in Mac (M1) cells in cirrhotic livers is biologically relevant. M1 macrophages are typically characterized by their pro-inflammatory functions, including the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), promotion of Th1 immune responses, and enhanced phagocytic and microbicidal activity. In the context of chronic liver disease like cirrhosis, an abundance of M1 macrophages suggests a sustained pro-inflammatory environment. This chronic inflammation is a key driver of hepatocyte injury, stellate cell activation, and fibrosis progression, ultimately contributing to liver scarring and functional decline.
  • For more information on M1 macrophage functions: PubMed search: M1 macrophage liver cirrhosis
• Decreased Mac (M2A) in Cirrhosis: The observed decrease in Mac (M2A) cells, while less pronounced than the M1 increase, is also notable. M2A macrophages are generally associated with Th2 immune responses, tissue repair, wound healing, and clearance of apoptotic cells. A relative reduction in this specific M2 subset might indicate a dysregulation in the liver's capacity for resolving inflammation and repairing tissue damage, or a shift towards other M2 subtypes (e.g., M2C, which are also associated with fibrosis). This imbalance, where pro-inflammatory M1 cells dominate over certain reparative M2 populations, can exacerbate liver injury and fibrosis.
  • For more information on M2 macrophage functions in liver: PubMed search: M2 macrophage liver fibrosis

Taken together, these findings indicate a significant shift in macrophage polarization within the cirrhotic liver, favoring a more pro-inflammatory M1 phenotype while showing a relative decrease in the M2A subset. This cellular reprogramming of the macrophage compartment likely contributes to the chronic inflammation and progressive fibrogenesis characteristic of liver cirrhosis.

Clinical or Translational Implications

The observed alterations in macrophage subset proportions in cirrhosis have several potential clinical implications:

• Biomarker Potential: The proportions of Mac (M1) and Mac (M2A) could serve as potential biomarkers for the severity or progression of liver cirrhosis, or to monitor the efficacy of anti-fibrotic therapies.
• Therapeutic Target: Modulating macrophage polarization, specifically reducing M1-like activity or promoting M2-like functions, presents a promising therapeutic strategy for mitigating inflammation and fibrosis in cirrhosis. For instance, interventions that re-polarize macrophages away from the M1 phenotype could help alleviate the chronic inflammatory burden in the liver.
• Disease Understanding: These findings deepen our understanding of the immune microenvironment in cirrhotic livers, highlighting the critical role of macrophage plasticity and dysregulation in the pathogenesis of the disease. This knowledge can guide the development of targeted immunomodulatory treatments.

9. Cell-Cell Interaction Patterns in Healthy and Cirrhotic Liver

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns using CellPhoneDB results derived from single-cell RNA-seq data of human liver tissue, comparing healthy and cirrhotic conditions. The plot_cci_dots tool was used to visualize significant ligand-receptor interactions between various cell types, with a focus on highlighting interactions present or enhanced in cirrhosis. The visualization emphasizes both the significance (-log10(p-value) represented by dot size) and the interaction strength (log2(mean expression) represented by dot color) of each gene pair between defined cell type pairs. A maximum of 80 cell-cell interactions per group (condition) passing a p-value cutoff of 0.05 and a mean expression cutoff of 0.01 are displayed.

Visual Summary

Two dot plots are provided, showcasing cell-cell interactions in the "cirrhosis" and "healthy" conditions respectively. Each plot displays interacting gene pairs on the x-axis and pairs of cell types (Cell_A | Cell_B) on the y-axis.

Key Observations from the Cirrhosis Plot:

• Increased Interaction Complexity: The cirrhosis plot exhibits a higher density and diversity of significant interactions compared to the healthy plot, suggesting a more complex and active cellular communication network in the diseased liver.
• Dominant Cell Types: Macrophages (Mac), T cells (CD4+ and CD8+), Endothelial cells (Endo), and Cholangiocytes are prominently involved in numerous strong interactions, both as sending and receiving cells.
• Highly Significant and Strong Interactions: Several large, brightly colored (yellow/green, indicating high log2(mean) and high -log10(p)) dots are observed, indicating highly significant and strong interactions. These include:
  • SPP1-integrin interactions: Notably, SPP1 (Osteopontin) interacting with various integrin complexes (e.g., ITGA4_ITGB1, ITGA5_ITGB1) is widespread, involving Macrophages, Endothelial cells, T cells, and Cholangiocytes.
  • Chemokine signaling: Interactions involving chemokines and their receptors, such as CCL3-CCR1, CCL4-CCR1, CCL5-CCR1, CXCL12-CXCR4, and CXCL16-CXCR6, are prominent among immune cells (Mac, T cells) and with other cell types.
  • ECM-related interactions: FN1-integrin and Collagen (Col4A1/2/4/6)-integrin complexes show significant interactions.
  • Angiogenic pathways: VEGFA-FLT1 interactions are evident, particularly involving Endothelial cells.
  • Immune modulation: Interactions such as GALECTIN9-HAVCR2 (TIM-3), HLA-E-KLRC1 (NKG2A), and MIF-CD74 are observed.

Key Observations from the Healthy Plot:

• Fewer Interactions: The healthy plot shows a sparser network of interactions, generally with smaller and less intensely colored dots, indicating fewer highly significant or strong interactions under homeostatic conditions.
• Homeostatic Interactions: Some interactions appear more prominent in healthy tissue, such as ANXA1-FPR1 in Macrophage-Macrophage interactions, which can be involved in inflammation resolution. TYROBP-CD44 also shows a strong signal in Mac|Mac.
• Common but Less Intense: Some interactions, like ICAM1-integrin complexes, are present in both conditions but appear less frequently or with lower strength in the healthy liver.

Comparative Summary:

The cirrhotic liver demonstrates a substantial upregulation and diversification of cell-cell interactions compared to the healthy state. Specifically, pathways related to fibrosis (SPP1-integrin, FN1-integrin, Collagen-integrin), inflammation and immune cell recruitment (chemokines, adhesion molecules), angiogenesis (VEGFA-FLT1), and immune modulation are significantly more active in cirrhosis.

Biological Interpretation

The observed cell-cell interaction patterns provide crucial insights into the pathological processes driving liver cirrhosis:

1. Exacerbated Inflammation and Immune Cell Trafficking: The abundance of chemokine-receptor interactions (e.g., CCL3/4/5-CCR1, CXCL12-CXCR4, CXCL16-CXCR6) between Macrophages and T cells, and with other resident liver cells, signifies persistent immune cell recruitment and activation. Macrophages play a central role as key drivers of inflammation and fibrosis in the liver. Adhesion molecules like ICAMs and CD99-CD99L2 facilitate immune cell extravasation and retention in the diseased parenchyma.
2. Pro-Fibrotic Signaling: The widespread and strong interactions involving SPP1 (Osteopontin) and various integrins (e.g., ITGA4_ITGB1, ITGA5_ITGB1) are highly indicative of active fibrosis. SPP1 is a well-known pro-fibrotic cytokine produced by macrophages and other cells, promoting ECM deposition and hepatic stellate cell activation PubMed Search: SPP1 liver fibrosis. Similarly, Fibronectin (FN1) and Collagen (Col4A1/2/4/6)-integrin interactions further underscore active ECM remodeling and fibrosis, which are hallmarks of cirrhosis. These interactions involve multiple cell types, including Macrophages, Endothelial cells, and Cholangiocytes, highlighting a complex multicellular interplay in fibrogenesis.
3. Angiogenesis and Vascular Remodeling: The prominent VEGFA-FLT1 interactions, particularly involving Endothelial cells, point to active angiogenesis in the cirrhotic liver. This pathological angiogenesis contributes to increased intrahepatic vascular resistance and portal hypertension, a major complication of cirrhosis.
4. Immune Dysregulation and Exhaustion: Interactions such as GALECTIN9-HAVCR2 (TIM-3), an immune checkpoint pathway, suggest mechanisms of immune cell exhaustion or regulation that may contribute to chronic inflammation and impaired pathogen clearance or even progression to hepatocellular carcinoma GeneCards HAVCR2. The presence of HLA-E-KLRC1 (NKG2A) also points to immunomodulatory pathways involving NK cells and T cells, which could affect their cytotoxic functions in cirrhosis.
5. Cholangiocyte and Endothelial Cell Contributions: Cholangiocytes and Endothelial cells, beyond their structural roles, actively participate in the pathological communication network through interactions with immune cells and ECM components, contributing to the overall inflammatory and fibrotic milieu.

Clinical or Translational Implications

The identified cell-cell interaction patterns in cirrhotic liver offer promising avenues for therapeutic intervention and biomarker development:

1. Targeting Fibrotic Pathways: The SPP1-integrin axis emerges as a highly relevant and pervasive pro-fibrotic pathway in cirrhosis. Therapeutic strategies aimed at blocking SPP1 or its cognate integrin receptors could directly mitigate liver fibrosis, potentially halting or reversing disease progression. This might involve small molecule inhibitors or antibody-based therapies.
2. Modulating Immune Cell Infiltration and Activation: Inhibiting key chemokine-receptor interactions (e.g., CCR1, CXCR4, CXCR6) could reduce the influx of pro-inflammatory and pro-fibrotic immune cells into the liver, thereby dampening chronic inflammation. Similarly, antagonists against adhesion molecules like ICAMs could prevent immune cell retention.
3. Anti-angiogenic Strategies: Targeting the VEGFA-FLT1 pathway could normalize the aberrant vasculature in cirrhosis, potentially reducing portal hypertension and improving liver function. Anti-VEGF therapies are already in clinical use for other conditions and might be repurposed or specifically developed for liver cirrhosis.
4. Immune Checkpoint Modulation: Given the activation of pathways like GALECTIN9-HAVCR2, therapeutic approaches to modulate immune checkpoints could be explored. Restoring effective anti-fibrotic or anti-tumor immune responses in the cirrhotic microenvironment might offer new strategies, especially considering the increased risk of hepatocellular carcinoma in cirrhosis.
5. Biomarker Discovery: The specific ligand-receptor pairs identified as highly active in cirrhosis could serve as novel diagnostic or prognostic biomarkers. Monitoring their expression or activity could help in assessing disease severity, predicting progression, or evaluating treatment efficacy in patients with cirrhosis. Further experimental validation would be crucial to confirm the functional significance of these interactions and their potential as therapeutic targets or biomarkers.

10. Condition-Specific Cell-Cell Interaction Patterns in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies cell-cell interactions (CCIs) that significantly differ between healthy liver tissue and liver tissue affected by cirrhosis, focusing on major tissue cells, immune cells, and stromal cells. The plot_dot_for_cci_with_signif_difference tool was used to visualize these patterns, highlighting interactions with high statistical significance (dot size) and strong scaled log expression (dot color) across individual samples grouped by condition. The analysis applied a maximum of 60 items per group (max_n_items_per_group=60) to focus on the most prominent interactions.

Visual Summary

The dot plot visualizes condition-specific cell-cell interaction patterns across individual samples. Each dot represents a unique cell-cell interaction (CCI Index) identified by a ligand-receptor pair and the interacting cell types. The color intensity of each dot corresponds to the scaled log strength of the interaction, while the size of the dot reflects its statistical significance (-log10(p-value)).

1. Dominance of Cirrhosis-Specific Interactions: A striking pattern emerges where samples from the "cirrhosis" condition (top section, highlighted in blue) exhibit a substantially higher number of strong and statistically significant cell-cell interactions compared to the "healthy" condition (bottom section, also highlighted in blue). The cirrhotic samples show numerous large, dark red dots across a wide range of interactions, indicating robust and highly prevalent signaling. In contrast, healthy samples generally display fewer, smaller, and lighter colored dots, suggesting a much less active or diverse interactome.
2. Key Interaction Categories in Cirrhosis:
   • Integrin-Mediated Interactions: A large cluster of highly active interactions in cirrhosis involves various integrin complexes (e.g., FN1_integrin, COL11A1_integrin, COL6A3_integrin, COL14A1_integrin, COL12A1_integrin, COL4A2_integrin, COL18A1_integrin). These interactions frequently occur between Hepatic stellate cells and Endothelial cells, as well as with different immune cell types (Macrophage, T cell, ILC). This suggests a strong role for extracellular matrix (ECM) remodeling and cell adhesion in the disease.
   • Immune Cell Cross-talk: Numerous interactions involve immune cells, particularly Macrophages ("Mac"), T cells ("T cell CD4+", "T cell CD8+"), NK cells, and ILCs, often interacting with Endothelial cells ("Endo") and Hepatic stellate cells ("st_cell"). This indicates a highly inflammatory and immune-activated microenvironment in cirrhotic liver. Specific examples include interactions involving HLA-G, LILRB1/2, TNF/TNFRSF family members, and various chemokines.
   • CXCL12-CXCR4 Axis: The CXCL12_CXCR4 interaction is notably strong and prevalent in cirrhosis, involving Hepatic stellate cells and T cells (CD4+).
   • Inflammatory Mediators: Interactions related to leukotrienes (e.g., LeukotrieneB4_byLTF4H_LTB4R) and prostaglandins (e.g., ProstaglandinE2_byPTGES2_PTGER4) are also prominent in cirrhotic samples, largely involving macrophages and T cells.
3. Absence of Strong Healthy-Specific Signals: The plot does not reveal any distinct, strong clusters of interactions uniquely or predominantly active in healthy samples. The interactions observed in healthy liver appear to represent baseline cellular communication, which is significantly amplified and diversified in the context of cirrhosis.

Biological Interpretation

The observed cell-cell interaction patterns underscore the profound cellular and molecular reprogramming that occurs in the liver during the progression of cirrhosis. The widespread increase in interaction strength and diversity in cirrhosis reflects a highly dynamic and pathological microenvironment characterized by chronic inflammation, progressive fibrosis, and immune cell infiltration.

Integrin Signaling and Extracellular Matrix Remodeling

The most striking feature is the extensive activation of integrin-mediated interactions, particularly involving Hepatic stellate cells (HSCs) and Endothelial cells.

• Signaling Pathways and Mechanisms: Integrins are crucial transmembrane receptors that mediate cell-ECM and cell-cell adhesion, playing a vital role in sensing and responding to the mechanical and biochemical properties of the ECM. In cirrhosis, chronic liver injury leads to excessive ECM deposition and stiffening, with components like Fibronectin (FN1) and various collagens (e.g., COL11A1, COL6A3, COL14A1, COL12A1, COL4A2, COL18A1) becoming prominent. When HSCs and Endothelial cells engage with these altered ECM components via specific integrins (e.g., α1β1, αVβ1, αVβ5), it triggers intracellular signaling pathways (e.g., FAK, Src, Rho-GTPases, MAPK, PI3K/Akt). These pathways promote HSC activation, proliferation, migration, and differentiation into myofibroblast-like cells, leading to increased synthesis of ECM proteins and perpetuating liver fibrosis. Endothelial cell integrin signaling is crucial for angiogenesis and vascular remodeling, which are dysregulated in cirrhosis.
• Context in Cirrhosis: Liver fibrosis is the central pathological process in cirrhosis, and HSCs are its primary drivers. The strong integrin signals confirm their sustained activation by the altered fibrotic milieu.
  • Reference: PubMed Search: "integrin hepatic stellate cell fibrosis liver cirrhosis"

Immune Cell Recruitment and Dysregulated Immune Responses

The abundance of interactions involving macrophages, T cells, NK cells, and ILCs points to a significant inflammatory and immune-mediated component in cirrhosis.

CXCL12-CXCR4 Axis:

• Signaling Pathways and Mechanisms: Chemokine (C-X-C motif) ligand 12 (CXCL12) and its receptor C-X-C chemokine receptor type 4 (CXCR4) form a crucial axis for immune cell trafficking, tissue repair, and pathological processes like fibrosis and tumor progression. Binding of CXCL12 to CXCR4 activates G-protein coupled receptor signaling, leading to downstream activation of various pathways (e.g., PI3K/Akt, MAPK, Rho GTPases). This promotes cell migration, survival, proliferation, and secretion of pro-fibrotic mediators.
• Context in Cirrhosis: The strong CXCL12-CXCR4 interaction involving Hepatic stellate cells and T cells suggests the recruitment and activation of these cells, contributing to both inflammation and fibrosis. CXCL12 produced by various liver cells can attract CXCR4-expressing immune cells and HSCs to sites of injury, thus exacerbating fibrogenesis and inflammation.
• Reference: GeneCards: CXCL12

HLA-G - LILRB1/2 Interactions:

• Signaling Pathways and Mechanisms: Human Leukocyte Antigen-G (HLA-G) is a non-classical MHC class I molecule expressed in various immune-privileged tissues and by certain pathological cells. It interacts with Leukocyte Immunoglobulin-Like Receptor B1 (LILRB1) and LILRB2 (also known as ILT2 and ILT4, respectively) on various immune cells (T cells, NK cells, macrophages, dendritic cells). This interaction typically delivers inhibitory signals, suppressing immune cell activation, proliferation, and cytokine production.
• Context in Cirrhosis: Its prominent involvement in cirrhosis, particularly with Hepatic stellate cells and multiple immune cell types, suggests an attempt by the cirrhotic microenvironment to modulate or suppress exaggerated immune responses, or potentially as a mechanism for immune evasion in the context of chronic inflammation and potentially hepatocellular regeneration/dysplasia.

TNF Family Interactions (TNFSF10-TNFRSF10B, TNF-TNFRSF1A/B):

• Signaling Pathways and Mechanisms: Tumor Necrosis Factor (TNF) and TNF Superfamily Ligand 10 (TNFSF10, also known as TRAIL) and their respective receptors (TNFRSF1A/B for TNF, TNFRSF10B for TRAIL) are critical regulators of inflammation, cell survival, and programmed cell death (apoptosis or necroptosis). These interactions activate complex signaling cascades (e.g., NF-κB, JNK, p38 MAPK) that can lead to pro-inflammatory gene expression or caspase-dependent apoptosis, depending on the cellular context and co-stimuli.
• Context in Cirrhosis: Their robust presence suggests heightened inflammatory responses and dysregulated cell death pathways, which are hallmarks of chronic liver injury and cirrhosis. These pathways can contribute to hepatocyte damage, perpetuation of inflammation, and activation of fibrogenic cells.

Inflammatory Lipid Mediators

Leukotriene and Prostaglandin Pathways:

• Signaling Pathways and Mechanisms: Leukotrienes (e.g., Leukotriene B4 acting on LTB4R) and prostaglandins (e.g., Prostaglandin E2 acting on PTGER4) are potent lipid mediators derived from arachidonic acid metabolism. They are crucial in inflammation and immune responses, acting through specific G-protein coupled receptors on target cells. They can promote chemotaxis, vasodilation, pain, and tissue damage, while also having some roles in immune regulation.
• Context in Cirrhosis: The strong interactions involving these mediators, particularly from macrophages to T cells, highlight the active inflammatory state in cirrhosis, contributing to immune cell recruitment and tissue pathology.

Clinical or Translational Implications

The distinct and pronounced cell-cell interaction patterns observed in cirrhosis offer several potential avenues for therapeutic intervention.

1. Anti-Fibrotic Therapies Targeting Integrins:
   • Implication: Given the central role of integrin-mediated interactions in Hepatic stellate cell activation and ECM remodeling, targeting these pathways could be highly effective in halting or reversing liver fibrosis. Inhibiting specific integrin subtypes or their ligands could prevent HSC activation, proliferation, and collagen production.
   • Therapeutic Agents: Integrin inhibitors, such as those targeting αVβ1, αVβ5, or αVβ8, are under investigation for fibrotic diseases. For example, molecules preventing the binding of FN1 or collagens to their respective integrin receptors on HSCs could modulate the fibrotic process. While no integrin inhibitor is currently approved specifically for liver fibrosis, this class of drugs holds significant promise.
     • Reference: PubMed Search: "integrin inhibitor liver fibrosis"
2. Immunomodulation and Anti-Inflammatory Strategies:
   • Implication: The widespread immune cell cross-talk and inflammatory mediator signaling suggest that immunomodulatory approaches could reduce chronic inflammation and liver damage.

Therapeutic Agents:

• CXCR4 Antagonists: Given the strong CXCL12-CXCR4 axis, particularly involving HSCs and T cells, CXCR4 antagonists (e.g., Plerixafor, approved for hematopoietic stem cell mobilization) could potentially reduce immune cell and HSC recruitment to the liver, thereby dampening inflammation and fibrosis.
  • Reference: PubMed Search: "CXCR4 antagonist liver fibrosis"
• Targeting TNF/TRAIL Pathways: While systemic TNF inhibition (e.g., using anti-TNF antibodies) has shown mixed results and potential adverse effects in liver disease, more targeted inhibition of specific TNF family receptor signaling that drives pathology without compromising protective immunity could be explored.
• Anti-inflammatory Lipid Modulators: Inhibitors of leukotriene or prostaglandin synthesis (e.g., 5-lipoxygenase inhibitors for leukotrienes) could alleviate inflammation in the cirrhotic liver, although careful consideration of side effects and systemic impact is needed.

3. Targeting Immune Checkpoints:
   • Implication: The strong HLA-G-LILRB1/2 interactions suggest potential immune suppressive mechanisms in the cirrhotic liver. Modulating this axis might enhance anti-fibrotic or anti-tumor immune responses, especially considering the increased risk of hepatocellular carcinoma in cirrhosis.
   • Therapeutic Agents: Strategies to block HLA-G/LILRB interactions are being explored in cancer immunotherapy and could potentially be repurposed to modulate immune responses in cirrhosis.

11. Cholangiocyte Condition-Specific Surfaceome Markers in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies surfaceome markers differentially expressed in Cholangiocytes between healthy and cirrhotic liver samples, utilizing single-cell RNA-seq data. The dot plot visualizes the mean expression and fraction of cells expressing each marker across various healthy and cirrhotic samples. The goal is to highlight potential disease-associated surface markers in cholangiocytes that could serve as biomarkers or therapeutic targets for cirrhosis.

Visual Summary

The dot plot displays a clear distinction in surfaceome marker expression profiles between cholangiocytes from healthy and cirrhotic liver samples.

• Cirrhosis-Associated Upregulation: A large cluster of markers on the left side of the plot (e.g., LMAN2, ATRAID, ASGR2, ABCC3, EFNA1, ERBB3, PMEPA1, ALCAM, CD9, TSPAN family members) shows markedly higher mean expression (darker red color) and a higher fraction of expressing cells (larger dot size) across most cirrhotic samples compared to healthy samples. This indicates a significant upregulation of these surface proteins in cholangiocytes during cirrhosis. The intensity and prevalence vary across individual cirrhotic samples, suggesting some heterogeneity.
• Healthy-Associated Upregulation: Conversely, a smaller group of markers towards the right end of the plot, most notably CD52, displays high mean expression and prevalence in healthy cholangiocytes but very low or negligible expression in cirrhotic cholangiocytes. This suggests a loss of these markers as cholangiocytes adapt to or are affected by the cirrhotic microenvironment.
• Sample Heterogeneity: While clear trends exist, there is some variability in marker expression across different samples within both the cirrhotic and healthy groups (e.g., 'cirrhotic1_cd45-A' vs. 'cirrhotic3_cd45-').

Biological Interpretation

The observed differential expression of surfaceome markers in cholangiocytes provides insights into the cellular adaptations and pathological processes occurring during liver cirrhosis. Focusing on markers upregulated in cirrhosis:

Cirrhosis-Associated Markers in Cholangiocytes:

1. EFNA1 (Ephrin-A1)
   • Observed Pattern: Markedly upregulated in Cholangiocytes from cirrhotic samples.
   • Signaling Pathways & Mechanisms: EFNA1 is a ligand for EphA receptors, part of the Eph/Ephrin signaling system crucial for cell-cell communication, regulating cell adhesion, migration, proliferation, and differentiation. In the context of liver disease, Eph/Ephrin signaling has been implicated in inflammation, angiogenesis, and fibrogenesis. Its upregulation on cholangiocytes in cirrhosis suggests increased pro-fibrotic signaling, altered cell-cell interactions, or an active role in biliary remodeling and inflammatory responses characteristic of chronic liver injury [1].
   • Therapeutic Potential: As a regulator of fibrogenic processes and cell-cell communication, EFNA1 or its corresponding EphA receptors could be potential therapeutic targets. Inhibiting EFNA1-EphA signaling might reduce aberrant cholangiocyte proliferation, migration, or interaction with pro-fibrotic cells, thereby mitigating fibrosis progression in cirrhosis. Therapeutic strategies could include neutralizing antibodies or small molecule inhibitors.
2. ERBB3 (HER3) and ERBB2 (HER2)
   • Observed Pattern: Both ERBB3 and ERBB2 show strong upregulation in Cholangiocytes from cirrhotic samples.
   • Signaling Pathways & Mechanisms: ERBB3 and ERBB2 are receptor tyrosine kinases (RTKs) from the epidermal growth factor receptor (EGFR/ERBB) family. ERBB2 often forms heterodimers with other ERBB family members, including ERBB3, activating downstream signaling pathways like PI3K/Akt/mTOR and Ras/Raf/MAPK. These pathways are critical for cell proliferation, survival, and differentiation. In liver injury and cirrhosis, aberrant activation of ERBB signaling can drive cholangiocyte proliferation (biliary hyperplasia), promote resistance to apoptosis, and contribute to fibrogenesis [2, 3].
   • Therapeutic Potential: The ERBB family is a well-established target in oncology. Tyrosine kinase inhibitors (TKIs) or monoclonal antibodies that block ERBB signaling might be repurposed for cirrhosis. Targeting ERBB3/ERBB2 could suppress pathogenic cholangiocyte proliferation, reduce inflammation, and attenuate fibrotic responses, offering a potential strategy to halt or reverse cirrhosis progression.
3. ABCC3 (MRP3)
   • Observed Pattern: Upregulated in Cholangiocytes from cirrhotic samples.
   • Signaling Pathways & Mechanisms: ABCC3 (Multidrug Resistance-associated Protein 3, MRP3) is an ATP-binding cassette (ABC) transporter located on the basolateral membrane of hepatocytes and cholangiocytes. It mediates the efflux of various endogenous and xenobiotic compounds, including conjugated bile acids, glucuronides, and sulfate conjugates, into the sinusoidal blood. In cholestatic liver diseases, including cirrhosis, ABCC3 is often upregulated in cholangiocytes as an adaptive mechanism to excrete accumulated toxic bile acids, thereby protecting cells from damage. Its upregulation contributes to altered bile acid homeostasis in cirrhosis [4].
   • Therapeutic Potential: While largely protective, sustained ABCC3 activation contributes to altered bile acid flux. Modulating ABCC3 activity could normalize bile acid metabolism, though careful consideration is needed to avoid exacerbating intracellular bile acid toxicity. Directly targeting ABCC3 could be complementary to current cholestasis treatments.
4. PMEPA1 (Prostate transmembrane protein, androgen induced 1)
   • Observed Pattern: Clearly upregulated in Cholangiocytes from cirrhotic samples.
   • Signaling Pathways & Mechanisms: PMEPA1 is a transmembrane protein known to interact with and regulate TGF-β signaling, a central pathway in liver fibrosis and cirrhosis that promotes the activation of hepatic stellate cells and extracellular matrix deposition, and influences cholangiocyte behavior. PMEPA1 can attenuate TGF-β-induced gene transcription by interacting with Smad proteins. Its upregulation in cholangiocytes during cirrhosis might reflect an attempted compensatory negative feedback to control excessive TGF-β signaling, or, depending on the context, contribute to altered cellular responses in the fibrotic microenvironment [5].
   • Therapeutic Potential: Given its direct involvement in TGF-β signaling, PMEPA1 represents a potential target for modulating fibrotic processes. Strategies could involve enhancing its inhibitory function or blocking its pro-fibrotic effects. Further research is needed to delineate its precise role in cholangiocyte-mediated fibrosis to guide therapeutic development.

Healthy-Associated Marker in Cholangiocytes:

1. CD52
   • Observed Pattern: Highly expressed in Cholangiocytes from healthy samples, with very low or negligible expression in cirrhotic samples.
   • Signaling Pathways & Mechanisms: CD52 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein found on various immune cells and, as shown here, on healthy cholangiocytes. Its precise function in cholangiocytes is not fully understood but may involve cell adhesion or immune modulation. Its significant downregulation in cirrhosis suggests a loss of a "healthy" cholangiocyte phenotype or an adaptation to the disease microenvironment, potentially indicating altered immune recognition or adhesion properties of cholangiocytes in cirrhosis [6].
   • Therapeutic Potential: While primarily known as an immune cell depletion target, its marked loss in cirrhotic cholangiocytes could serve as a biomarker for disease progression or a shift in cholangiocyte identity during the disease.

Clinical or Translational Implications

The identification of condition-specific surfaceome markers on cholangiocytes in cirrhosis offers several translational avenues:

• Biomarkers: Markers like EFNA1, ERBB3/ERBB2, ABCC3, and PMEPA1, which are significantly upregulated in cirrhotic cholangiocytes, could serve as novel diagnostic or prognostic biomarkers for liver fibrosis and cirrhosis. Their expression levels could potentially correlate with disease severity or progression.
• Therapeutic Targets: The surface localization of these markers makes them highly accessible for therapeutic intervention.
  • Targeting Profibrotic Pathways: Upregulated markers like EFNA1 and the ERBB3/ERBB2 axis directly implicate pro-fibrotic signaling and cholangiocyte proliferation. Developing small molecules or monoclonal antibodies to block these receptors or their ligands could mitigate aberrant cholangiocyte responses and reduce fibrosis. Agents currently used in oncology (e.g., ERBB inhibitors) could be explored for repurposing.
  • Modulating Cholestasis: ABCC3's role in bile acid transport suggests that its modulation could influence bile acid homeostasis, potentially improving outcomes in cholestatic cirrhosis, though the precise therapeutic approach (inhibition vs. enhancement) needs careful validation.
  • TGF-β Pathway Modulation: PMEPA1's involvement in TGF-β signaling provides another potential avenue. Strategies to modulate PMEPA1 activity could indirectly control the critical pro-fibrotic TGF-β pathway.
• Drug Development: These findings prioritize specific surface molecules on cholangiocytes for targeted drug development, allowing for cell-type-specific interventions with potentially fewer off-target effects.

References:

1. EFNA1 (Ephrin-A1) Gene Information: https://www.genecards.org/cgi-bin/carddisp.pl?gene=EFNA1
2. ERBB3 (HER3) Gene Information: https://www.genecards.org/cgi-bin/carddisp.pl?gene=ERBB3
3. ERBB2 (HER2) Gene Information: https://www.genecards.org/cgi-bin/carddisp.pl?gene=ERBB2
4. ABCC3 (MRP3) Gene Information: https://www.genecards.org/cgi-bin/carddisp.pl?gene=ABCC3
5. PMEPA1 Gene Information: https://www.genecards.org/cgi-bin/carddisp.pl?gene=PMEPA1
6. CD52 Gene Information: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD52

12. Macrophage Condition-Specific Surfaceome Markers in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of surfaceome markers in Macrophage cells derived from human liver tissue, comparing healthy individuals to those with cirrhosis. The markers were identified using a one-vs-rest comparison strategy for each condition (cirrhosis vs. others, healthy vs. others) and are restricted to surface proteins (surfaceome markers). The goal is to highlight distinct surface marker profiles that characterize macrophages in healthy versus cirrhotic liver, providing insights into their altered states and potential therapeutic targets.

Visual Summary

The dot plot visualizes the mean expression level (color intensity, ranging from light red to dark red) and the fraction of cells expressing a given marker (dot size, larger dot indicates a higher fraction of expressing cells) across different samples within the 'Macrophage' cell type. Samples are grouped by condition: 'cirrhosis' (top section) and 'healthy' (bottom section).

Key observations include:

• Cirrhosis-Enriched Markers: A prominent group of markers, largely on the left side of the plot (e.g., JAML, EVI2A, GPR65, FCGR2A, BSG, CD300A, FCGR1A, CD33, TNFRSF14, LRP1, PTAFR, SIGIRR), display high mean expression (dark red) and a high fraction of expressing cells (large dots) almost exclusively in samples from the cirrhosis condition. These markers show minimal to no expression in healthy samples. This indicates a distinct, highly activated or altered surface phenotype for macrophages in cirrhotic liver.
• Healthy-Enriched Markers: Conversely, a smaller set of markers towards the right of the plot (e.g., CD1D, LLRA2, SLC11A1, SLC40A1, PRNP, AXL) show higher expression and prevalence predominantly in healthy samples. Their expression is markedly reduced or absent in cirrhosis samples, suggesting they might characterize macrophages involved in liver homeostasis or a less inflammatory state.
• Sample-Level Variability: Within each condition, there is some variability in expression levels and cell fractions across individual samples, particularly for healthy samples, suggesting heterogeneity even within what is broadly defined as "healthy" or "cirrhosis" contexts.

Biological Interpretation

The distinct surfaceome marker profiles observed on macrophages between healthy and cirrhotic liver suggest a profound functional reprogramming of these cells in the disease state. Macrophages, including resident Kupffer cells and monocyte-derived macrophages, are crucial players in liver immunity, injury, and repair. Their altered surface markers provide clues about their activation state, interaction with other cells, and contribution to disease pathology.

Markers Enriched in Cirrhosis Macrophages

The upregulation of specific surface markers on macrophages in cirrhosis points towards their involvement in chronic inflammation, immune activation, and fibrogenesis.

• FCGR1A (CD64) and FCGR2A (CD32): These are high-affinity and low-affinity Fc-gamma receptors, respectively, which bind to the Fc portion of IgG antibodies. Their upregulation indicates increased immune activation and potential for immune complex-mediated inflammation. In cirrhosis, these receptors can mediate phagocytosis, antigen presentation, and the release of pro-inflammatory cytokines, contributing to the persistent inflammatory state and driving liver injury and fibrosis.

References

• GeneCards FCGR1A: https://www.genecards.org/cgi-bin/carddisp.pl?gene=FCGR1A
• GeneCards FCGR2A: https://www.genecards.org/cgi-bin/carddisp.pl?gene=FCGR2A
• PubMed search: "Fc gamma receptor liver cirrhosis macrophage" https://pubmed.ncbi.nlm.nih.gov/?term=Fc+gamma+receptor+liver+cirrhosis+macrophage

• CD33: A sialic acid-binding immunoglobulin-like lectin 3 (Siglec-3), primarily expressed on myeloid cells. While often considered an inhibitory receptor, its role can be context-dependent. Its upregulation in cirrhosis macrophages could reflect an altered immunoregulatory state, potentially contributing to immune dysfunction or failed resolution of inflammation in the cirrhotic microenvironment.
  • Reference: GeneCards CD33: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD33
• BSG (CD147): Also known as Extracellular Matrix Metalloproteinase Inducer (EMMPRIN). CD147 is a glycoprotein that stimulates the production of matrix metalloproteinases (MMPs) by various cells, promoting extracellular matrix remodeling and degradation. Its high expression on cirrhotic macrophages suggests their active participation in the breakdown and subsequent aberrant deposition of extracellular matrix, a hallmark of liver fibrosis and cirrhosis. It also plays roles in inflammation and angiogenesis.
  • Reference: GeneCards BSG: https://www.genecards.org/cgi-bin/carddisp.pl?gene=BSG
• TNFRSF14 (HVEM): Herpesvirus entry mediator, a TNF receptor superfamily member, involved in both co-stimulatory and co-inhibitory immune signaling by interacting with ligands like LIGHT and BTLA. Upregulation on cirrhotic macrophages indicates active immune cell crosstalk, potentially influencing the balance between pro-inflammatory and anti-inflammatory responses in the liver, which is often disrupted in cirrhosis.
  • Reference: GeneCards TNFRSF14: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TNFRSF14

Markers Enriched in Healthy Macrophages

The presence of specific markers on macrophages in healthy liver suggests their roles in maintaining tissue homeostasis, resolving minor injury, and regulating iron metabolism.

• AXL: A receptor tyrosine kinase that binds Growth Arrest-Specific protein 6 (GAS6). AXL signaling is crucial for cell survival, proliferation, migration, and efferocytosis (clearance of apoptotic cells). Its higher expression in healthy macrophages likely reflects their critical role in clearing cellular debris and maintaining tissue integrity, as well as promoting an anti-inflammatory and pro-resolving macrophage phenotype, which is essential for liver health. Its downregulation in cirrhosis could contribute to impaired resolution of injury.
  • Reference: GeneCards AXL: https://www.genecards.org/cgi-bin/carddisp.pl?gene=AXL
• SLC40A1 (Ferroportin-1): The sole known mammalian iron exporter. Macrophages, particularly Kupffer cells, are critical for iron recycling and maintaining systemic iron homeostasis. Higher expression of ferroportin-1 in healthy liver macrophages indicates a functional state of iron efflux, preventing iron accumulation. Iron overload is a significant contributor to oxidative stress and liver injury in cirrhosis, suggesting that a reduction or dysregulation of ferroportin-1 in cirrhotic macrophages could exacerbate disease progression by impairing iron handling.
  • Reference: GeneCards SLC40A1: https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC40A1
• CD1D: A major histocompatibility complex (MHC) class I-like molecule involved in presenting lipid antigens to invariant NKT (iNKT) cells. These interactions are vital for immune regulation in the liver. Higher CD1D expression on healthy macrophages suggests a balanced immune environment supported by iNKT cell surveillance, which can be critical for anti-tumor immunity and control of inflammation. Its reduced expression in cirrhosis might indicate a disrupted lipid antigen presentation pathway and altered iNKT cell function, contributing to immune dysregulation.
  • Reference: GeneCards CD1D: https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD1D

Clinical or Translational Implications

The identified condition-specific surfaceome markers on macrophages offer several potential clinical and translational implications for liver cirrhosis:

• Diagnostic and Prognostic Biomarkers: Markers like FCGR1A, FCGR2A, CD33, and BSG, which are highly expressed in cirrhotic macrophages but absent in healthy ones, could serve as novel diagnostic or prognostic biomarkers for liver cirrhosis progression or severity, potentially detectable via biopsy or circulating macrophage analysis. Conversely, reduced expression of AXL, SLC40A1, and CD1D might also indicate disease.

Therapeutic Targets

• Targeting Pro-fibrotic/Inflammatory Macrophages: Upregulated receptors in cirrhosis, such as FCGR1A/FCGR2A (Fc-gamma receptors) and BSG (CD147), represent promising therapeutic targets. Modulating FcR signaling could dampen chronic inflammation and immune complex-mediated injury. Inhibitors of CD147, or its downstream MMPs, could reduce ECM remodeling and fibrosis. Neutralizing antibodies or small molecule inhibitors could be explored to block these receptors or their associated signaling pathways, thereby reprogramming macrophages away from a pro-fibrotic and pro-inflammatory state.
  • Related Therapeutic Agents: Anti-FcR antibodies (though typically used for depletion, modulation could be explored), anti-CD147 antibodies, or MMP inhibitors are examples of agent classes.
• Restoring Homeostatic Macrophage Functions: The downregulation of markers like AXL and SLC40A1 in cirrhosis suggests a loss of beneficial macrophage functions. Strategies to enhance AXL signaling could promote efferocytosis and dampen inflammation. Restoring ferroportin-1 activity via gene therapy or pharmacological agents could improve iron handling, mitigating oxidative stress and liver damage in cirrhosis patients with iron dysregulation.
  • Related Therapeutic Agents: AXL agonists (under investigation for other diseases), iron chelators (indirectly affecting ferroportin function or iron overload).
• Immunomodulation via CD1D: Modulating CD1D-iNKT cell interactions, perhaps through specific lipid antigens, could rebalance immune responses in the liver, steering them towards anti-inflammatory or anti-fibrotic outcomes. However, this is a complex area requiring precise control over iNKT cell activation.

Further research involving functional validation (e.g., *in vitro* macrophage polarization assays, *in vivo* disease models) would be essential to confirm the precise roles of these markers and validate their potential as therapeutic targets in liver cirrhosis.

13. Hepatic Stellate Cell Condition-Specific Surfaceome Markers in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies surfaceome markers differentially expressed in Hepatic stellate cells (HSCs) when comparing cirrhosis samples to other conditions (one-vs-rest) and healthy samples to other conditions (one-vs-rest). The results are visualized using a dot plot, where the color intensity represents the mean expression level of a marker within a group, and the size of the dot represents the fraction of cells in that group expressing the marker. The analysis utilized stringent criteria, including a non-zero percentage score cutoff and a fold-change cutoff, to identify robust markers. This provides insight into the altered surface protein landscape of HSCs during liver fibrosis and cirrhosis.

Visual Summary

The dot plot displays surfaceome marker expression across individual cirrhotic and healthy samples, grouped by condition.

• Condition-Specific Expression: There is a clear segregation of markers based on the liver condition. Markers on the left side of the plot (e.g., CD74, ENG, ITM2C, EMP3, ITGA1, TFPI, CD44, HLA-DRB1) show high mean expression (darker red dots) and a high fraction of expressing cells (larger dot sizes) predominantly in the cirrhotic samples. Conversely, markers on the right side (e.g., CD9, TM4SF1, APP, BCAM, AXL, MCAM, NTRK2, NGFR, JAG1, SDC2) exhibit strong expression and prevalence in the healthy samples.
• Heterogeneity within Conditions: While general patterns are clear, some heterogeneity is observed within samples of the same condition. For instance, cirrhotic1_cd45-A and cirrhotic2_cd45- samples show particularly high expression for many cirrhosis-associated markers. Similarly, healthy3_cd45-A and healthy3_cd45-B show strong expression of many healthy-associated markers.
• Mean Expression and Cell Fraction: Markers like ENG, ITGA1, and CD44 in cirrhosis, and CD9, AXL, and JAG1 in healthy samples, are characterized by both high mean expression (dark red) and a large fraction of expressing cells (large dot size), indicating they are robust and widespread markers for their respective conditions in Hepatic stellate cells.
• Sample Cell Counts: The bar chart on the right indicates the number of Hepatic stellate cells captured per sample, ranging from 32 to 362 cells, ensuring sufficient cellular representation for marker analysis in most groups.

Biological Interpretation

The differential expression of surfaceome markers in Hepatic stellate cells (HSCs) reflects their distinct functional states in healthy versus cirrhotic liver. In cirrhosis, HSCs undergo activation into myofibroblast-like cells, which are the primary drivers of fibrogenesis. The identified markers highlight key pathways involved in this activation and the diseased microenvironment.

Markers Enriched in Cirrhotic Hepatic Stellate Cells

These markers often indicate HSC activation, enhanced matrix interaction, inflammatory signaling, or acquired antigen-presenting capabilities.

1. ENG (Endoglin / CD105)
   • Signaling Pathways & Mechanisms: ENG is a co-receptor for the Transforming Growth Factor-beta (TGF-β) receptor complex, crucial for regulating angiogenesis and fibrosis. In activated HSCs, upregulation of ENG enhances TGF-β signaling, promoting pro-fibrotic responses such as increased extracellular matrix (ECM) production and cell proliferation. It also plays a role in regulating angiogenesis, a critical component of advanced liver disease and portal hypertension.
   • Therapeutic Potential: Given its central role in both TGF-β signaling and angiogenesis, ENG is a highly attractive therapeutic target for liver fibrosis and cirrhosis. Inhibiting ENG could reduce HSC activation and proliferation, attenuate ECM deposition, and limit pathological angiogenesis.
   • Therapeutic Agents: Monoclonal antibodies targeting ENG, such as TRC105, have been developed and evaluated in clinical trials for cancer, showing potential for repurposing in fibrotic diseases.

References:

• GeneCards (ENG): https://www.genecards.org/cgi-bin/carddisp.pl?gene=ENG
• PubMed (ENG liver fibrosis): https://pubmed.ncbi.nlm.nih.gov/?term=ENG+endoglin+liver+fibrosis

2. ITGA1 (Integrin Alpha 1 / CD49a)
   • Signaling Pathways & Mechanisms: ITGA1 forms a heterodimer with ITGB1 (CD29) to create Integrin VLA-1, a receptor for collagens (type I, IV) and laminin. Its upregulation in cirrhotic HSCs indicates enhanced adhesion to the abundant and altered fibrotic ECM. This increased cell-matrix interaction is critical for HSC survival, migration, and sustained activation in the diseased liver.
   • Therapeutic Potential: Disrupting the interaction between activated HSCs and their fibrotic environment by targeting ITGA1 could reduce HSC activation, promote apoptosis, and attenuate fibrosis progression.
   • Therapeutic Agents: Integrin inhibitors have been explored for various fibrotic conditions, and specific ITGA1 inhibitors could be developed or repurposed for liver fibrosis.

References:

• GeneCards (ITGA1): https://www.genecards.org/cgi-bin/carddisp.pl?gene=ITGA1
• PubMed (ITGA1 liver fibrosis): https://pubmed.ncbi.nlm.nih.gov/?term=ITGA1+integrin+hepatic+stellate+cell+fibrosis

3. CD44
   • Signaling Pathways & Mechanisms: CD44 is a multi-functional cell adhesion molecule and receptor for hyaluronic acid (HA), osteopontin, and other ECM components. In activated HSCs, CD44 is involved in cell migration, proliferation, and survival. It facilitates the uptake of HA, which is elevated in fibrotic livers and contributes to disease progression. CD44 also modulates signaling pathways, contributing to inflammation and fibrogenesis.
   • Therapeutic Potential: Targeting CD44 could interfere with HSC activation, migration, and their interactions with the fibrotic microenvironment. This makes it a potential target for anti-fibrotic therapy.
   • Therapeutic Agents: Antibodies targeting CD44 or small molecule inhibitors are under investigation, primarily in oncology, but hold potential for fibrotic diseases.

References:

• GeneCards (CD44): https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD44
• PubMed (CD44 liver fibrosis): https://pubmed.ncbi.nlm.nih.gov/?term=CD44+liver+fibrosis

4. LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1)
   • Signaling Pathways & Mechanisms: LRP1 is a large endocytic and signaling receptor with diverse functions, including the clearance of various ligands such as ECM components (e.g., collagen fragments), proteases (e.g., MMPs), and growth factors. Its upregulation in cirrhotic HSCs may reflect increased scavenging activity of degraded ECM components or altered signaling that contributes to HSC activation and persistence. LRP1 can also modulate receptor tyrosine kinase signaling, impacting cell migration and survival.
   • Therapeutic Potential: Modulating LRP1 activity could influence ECM turnover and growth factor signaling in HSCs, potentially impacting fibrosis. However, its complex nature requires careful study to identify specific contexts for therapeutic intervention.
   • Therapeutic Agents: Currently, no specific LRP1-targeted agents are in clinical use for liver fibrosis, but research into its role in various diseases suggests it is a viable target.

References:

• GeneCards (LRP1): https://www.genecards.org/cgi-bin/carddisp.pl?gene=LRP1
• PubMed (LRP1 hepatic stellate cell fibrosis): https://pubmed.ncbi.nlm.nih.gov/?term=LRP1+hepatic+stellate+cell+fibrosis

5. HLA-DRB1, HLA-DPA1, HLA-DPB1 (MHC Class II Genes)
   • Signaling Pathways & Mechanisms: These genes encode components of Major Histocompatibility Complex (MHC) class II molecules, typically found on professional antigen-presenting cells (APCs). Their robust expression on cirrhotic HSCs suggests that these cells may acquire or enhance antigen-presenting capabilities. This could contribute to chronic inflammation and immune responses in the fibrotic liver by presenting antigens to CD4+ T cells, thereby perpetuating immune-mediated injury and fibrogenesis.
   • Therapeutic Potential: While directly targeting MHC class II on HSCs for fibrosis treatment is complex due to potential systemic immunosuppression, their expression indicates a pro-inflammatory role for activated HSCs. Modulating this immune interaction could be part of a broader anti-inflammatory strategy.
   • Therapeutic Agents: Not direct therapeutic targets for fibrosis per se, but their presence points towards inflammatory mechanisms that could be addressed by immunomodulatory therapies.

References:

• GeneCards (HLA-DRB1): https://www.genecards.org/cgi-bin/carddisp.pl?gene=HLA-DRB1
• PubMed (HSC MHC II fibrosis): https://pubmed.ncbi.nlm.nih.gov/?term=hepatic+stellate+cell+MHC+II+fibrosis

Markers Enriched in Healthy Hepatic Stellate Cells

These markers may reflect quiescent HSCs or those involved in homeostatic functions. Their downregulation in cirrhosis suggests a loss of these protective or normal functions.

1. CD9
   • Signaling Pathways & Mechanisms: CD9 is a tetraspanin involved in various cellular processes, including cell adhesion, migration, proliferation, and differentiation, by forming complexes with other membrane proteins. In HSCs, CD9 has been associated with maintaining a quiescent state. Its robust expression in healthy HSCs and likely downregulation in cirrhosis suggest that its loss contributes to HSC activation and the transition to a pro-fibrotic phenotype.
   • Therapeutic Potential: Restoring CD9 expression or its associated functions in activated HSCs could be a strategy to induce quiescence or reduce their pro-fibrotic activity. As a marker, its decrease can serve as an indicator of HSC activation.
   • Therapeutic Agents: While no specific CD9-targeting agents are in development for liver fibrosis, understanding its role could inspire strategies that promote HSC quiescence or de-activation.

References:

• GeneCards (CD9): https://www.genecards.org/cgi-bin/carddisp.pl?gene=CD9
• PubMed (CD9 hepatic stellate cell quiescence): https://pubmed.ncbi.nlm.nih.gov/?term=CD9+hepatic+stellate+cell+quiescence

2. AXL
   • Signaling Pathways & Mechanisms: AXL is a receptor tyrosine kinase that binds to Growth Arrest-specific 6 (GAS6). It generally promotes cell survival, proliferation, and migration, and is involved in efferocytosis. While often linked to disease progression in other contexts, its strong expression in *healthy* HSCs here suggests a potential role in maintaining HSC quiescence, mediating responses to minor physiological cues, or regulating efferocytosis to clear apoptotic cells, which is crucial for tissue homeostasis. Its observed downregulation in cirrhosis may indicate a disruption of these normal regulatory or clearance mechanisms.
   • Therapeutic Potential: If AXL's role in healthy HSCs is primarily homeostatic or protective, strategies to preserve or enhance its function could be beneficial. However, due to its complex and often pro-fibrotic/pro-cancerous roles in other settings, its modulation would require precise, context-specific approaches.
   • Therapeutic Agents: AXL inhibitors are under development for various cancers, and their application in liver fibrosis would necessitate detailed mechanistic studies specific to HSCs.

References:

• GeneCards (AXL): https://www.genecards.org/cgi-bin/carddisp.pl?gene=AXL
• PubMed (AXL hepatic stellate cell): https://pubmed.ncbi.nlm.nih.gov/?term=AXL+hepatic+stellate+cell

3. JAG1 (Jagged 1)
   • Signaling Pathways & Mechanisms: JAG1 is a ligand for Notch receptors, initiating the Notch signaling pathway, which is critical for cell fate determination, differentiation, proliferation, and apoptosis. In the liver, Notch signaling has complex roles in both normal development and disease, including HSC activation. Its higher expression in healthy HSCs might imply a role in maintaining HSC quiescence, regulating normal liver repair processes, or fine-tuning communication with other liver cells to preserve homeostasis.
   • Therapeutic Potential: Modulating Notch signaling is complex. If JAG1 in healthy HSCs contributes to beneficial regulatory functions, its observed reduction in cirrhosis could contribute to disease progression. Therapeutic strategies might aim to restore a balanced Notch signaling, potentially through targeted agonists.
   • Therapeutic Agents: Broad Notch inhibitors (e.g., gamma-secretase inhibitors) exist but have systemic side effects. More specific strategies focusing on particular Notch ligands or receptors are being explored.

References:

• GeneCards (JAG1): https://www.genecards.org/cgi-bin/carddisp.pl?gene=JAG1
• PubMed (JAG1 hepatic stellate cell Notch): https://pubmed.ncbi.nlm.nih.gov/?term=JAG1+hepatic+stellate+cell+Notch+fibrosis

4. NGFR (Nerve Growth Factor Receptor / p75NTR)
   • Signaling Pathways & Mechanisms: NGFR is a member of the TNF receptor superfamily that binds various neurotrophins. In non-neuronal cells like HSCs, NGFR can mediate both pro-survival and pro-apoptotic signals depending on context and co-receptors. Its expression in healthy HSCs might be involved in maintaining quiescence or promoting the apoptosis of activated HSCs as part of fibrosis resolution. Its downregulation in cirrhosis could contribute to the persistent survival and activation of HSCs.
   • Therapeutic Potential: Enhancing NGFR signaling, particularly pathways that favor apoptosis of activated HSCs or promote quiescence, could be a therapeutic avenue to counteract fibrosis.
   • Therapeutic Agents: Modulators of neurotrophin signaling and NGFR are being investigated, predominantly in neurological disorders, but their potential in liver fibrosis is an emerging area.

References:

• GeneCards (NGFR): https://www.genecards.org/cgi-bin/carddisp.pl?gene=NGFR
• PubMed (NGFR hepatic stellate cell fibrosis): https://pubmed.ncbi.nlm.nih.gov/?term=NGFR+hepatic+stellate+cell+fibrosis

Clinical or Translational Implications

The distinct surfaceome profiles of Hepatic stellate cells in cirrhotic versus healthy livers offer significant clinical and translational implications:

• Biomarkers of Disease Progression: The markers highly expressed in cirrhotic HSCs, such as ENG, ITGA1, CD44, and the MHC Class II molecules, could serve as novel biomarkers for identifying activated HSCs in the fibrotic liver. These could potentially be assessed in liver biopsies or even non-invasively if shed forms or associated circulating factors are discovered. Conversely, the reduction of healthy-associated markers like CD9, AXL, and JAG1 could indicate the loss of HSC quiescence and progression toward fibrosis.
• Therapeutic Targets for Cirrhosis: The upregulated surface markers in cirrhotic HSCs represent promising therapeutic targets to halt or reverse fibrosis.
  • Anti-fibrotic strategies: Targeting ENG could inhibit TGF-β-driven fibrogenesis and pathological angiogenesis. Blocking ITGA1 could disrupt the critical adhesion of activated HSCs to the fibrotic ECM, leading to their deactivation or apoptosis. Inhibiting CD44 could disrupt key cellular processes contributing to HSC activation and survival.
  • Immunomodulatory approaches: The expression of MHC Class II molecules on cirrhotic HSCs highlights their potential role in immune cell interactions, suggesting that specific immunomodulatory therapies could be developed to dampen chronic inflammation in the liver.
  • Restoring quiescence: Understanding the roles of markers like CD9, AXL, JAG1, and NGFR in healthy HSCs could pave the way for therapies aimed at restoring HSC quiescence or promoting their de-activation, thereby preventing or reversing fibrosis.
• Development of Targeted Therapies: The surfaceome nature of these markers makes them highly accessible for drug development. Monoclonal antibodies or small molecule inhibitors could be designed to specifically target these proteins on activated HSCs, minimizing off-target effects on other cell types. Existing agents (e.g., anti-ENG antibodies used in oncology) could be explored for repurposing in liver fibrosis, following rigorous preclinical and clinical validation.
• Precision Medicine: A deeper understanding of these markers could enable a more personalized approach to treating cirrhosis, where therapies are tailored based on the specific molecular signature of a patient's HSCs.

14. Surfaceome Marker Expression in CD4+ T cells in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis identifies and visualizes surfaceome marker gene expression in CD4+ T cells isolated from liver tissue, comparing healthy individuals to those with cirrhosis. The dot plot displays the mean expression level (color intensity) and the fraction of cells expressing each gene (dot size) for individual samples, clustered by condition. The markers were selected based on a one-vs-rest comparison, aiming to identify genes highly expressed in CD4+ T cells within either the healthy or cirrhotic condition, while enriching for surfaceome proteins. The goal is to highlight condition-specific surface molecules that could serve as biomarkers or therapeutic targets.

Visual Summary

The dot plot visualizes the expression of eight surfaceome markers (IL2RG, LY6E, GYPC, SIT1, CD40LG, BST2, SIGIRR, HLA-DRA) across various samples of CD4+ T cells, grouped into 'cirrhosis' and 'healthy' conditions.

1. Condition-Specific Expression: A striking pattern is observed where most of the displayed markers (IL2RG, LY6E, GYPC, SIT1, CD40LG, BST2, SIGIRR) exhibit notably higher mean expression (darker red color) and are expressed in a larger fraction of cells (larger dot size) within the 'cirrhosis' samples compared to the 'healthy' samples.
2. HLA-DRA: This marker shows a different pattern. While generally expressed more highly and in more cells in several 'cirrhosis' samples, it also demonstrates some baseline expression in a few 'healthy' samples (e.g., healthy4_cd45-, healthy3_cd45-A, healthy4_cd45+), albeit often at lower mean expression levels and in a smaller fraction of cells than in highly expressing cirrhotic samples.
3. Clustering by Condition: The samples clearly cluster by their condition, with all 'cirrhosis' samples grouped together and all 'healthy' samples grouped together, indicating that the identified markers effectively delineate these two states.
4. LMAN2 Absence: The marker LMAN2 appears to have minimal to no expression in any of the displayed samples from either condition, suggesting it might have been selected by the initial criteria but did not show significant expression in this specific visualization context, or its expression was below the plotting threshold. *Given it's plotted, it's likely its score was above threshold, but actual expression values are very low.*

In summary, the plot strongly indicates an activated or altered phenotype of CD4+ T cells in cirrhotic liver, characterized by the upregulation of several immunologically relevant surface proteins.

Biological Interpretation

The identified surfaceome markers provide insights into the altered state of CD4+ T cells during liver cirrhosis, suggesting increased activation, inflammatory responses, and potential immunoregulatory roles.

• IL2RG (Interleukin-2 Receptor Gamma Chain): This is a crucial component of the receptor for several interleukins, including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, often called the common gamma chain. IL-2 signaling is fundamental for T cell proliferation, survival, and differentiation. Upregulation of IL2RG in cirrhotic CD4+ T cells suggests an activated state with enhanced responsiveness to these cytokines, driving T cell expansion and effector functions in the inflammatory liver environment.
  • Signaling Pathways: IL-2/IL-2R signaling, JAK-STAT pathway activation.
  • Biological Mechanism: Essential for lymphocyte development and maintenance of regulatory T cells, as well as expansion of effector T cells. Its increased expression points towards active T cell immune responses in cirrhosis.
  • GeneCards: IL2RG
• LY6E (Lymphocyte Antigen 6 Complex Locus E): LY6E is a glycosylphosphatidylinositol (GPI)-anchored protein often associated with T cell activation and differentiation, particularly in inflammatory contexts. While its precise function in T cells is still under investigation, it can be involved in modulating immune responses and has been linked to T cell motility and survival. Its increased expression in cirrhotic CD4+ T cells could mark a specific activated or pathogenic T cell subset.
  • Signaling Pathways: Potentially involved in TCR signaling modulation or cytokine receptor signaling indirectly.
  • Biological Mechanism: May contribute to T cell activation, survival, and trafficking in chronic inflammation.
  • GeneCards: LY6E
• GYPC (Glycophorin C): Glycophorins are typically associated with red blood cells, playing a role in membrane stability and adhesion. However, non-erythroid expression, particularly in endothelial cells, has been reported. Its presence as a surfaceome marker on CD4+ T cells, if validated, is less conventional and could indicate a unique stress response, specific T cell subset, or perhaps a novel role in T cell-stromal interactions within the cirrhotic liver microenvironment.
  • Signaling Pathways: Not typically associated with canonical T cell signaling. Potentially involved in adhesion or cell membrane integrity.
  • Biological Mechanism: Unconventional for T cells; could indicate specific adhesive properties or cellular stress.
  • GeneCards: GYPC
• SIT1 (Signal Transducing Adaptor Family Member 1): Also known as SCAP2, SIT1 is an adaptor protein involved in T cell receptor (TCR) signaling. It negatively regulates TCR-mediated activation, proliferation, and cytokine production in T cells. Upregulation of SIT1 in cirrhotic CD4+ T cells might represent a negative feedback mechanism attempting to temper excessive T cell activation, or it could mark exhausted or anergic T cell states in chronic inflammation.
  • Signaling Pathways: Modulates TCR signaling, associated with SHP-1/2 phosphatases.
  • Biological Mechanism: Dampens T cell activation, proliferation, and cytokine secretion. Its upregulation could suggest an attempt to control inflammation or indicate T cell exhaustion.
  • GeneCards: SIT1
• CD40LG (CD40 Ligand / CD154): CD40LG is a transmembrane protein expressed primarily on activated CD4+ T cells. It binds to CD40 on antigen-presenting cells (APCs), B cells, and other cells, forming the critical CD40-CD40L axis. This interaction is essential for costimulation, B cell activation, immunoglobulin class switching, and the generation of robust cellular and humoral immune responses. Its high expression in cirrhotic CD4+ T cells is a strong indicator of T cell activation and enhanced immune crosstalk within the liver, contributing to inflammation and fibrosis.
  • Signaling Pathways: CD40-CD40L costimulatory pathway.
  • Biological Mechanism: Crucial for T cell-APC interaction, B cell activation, and effective adaptive immunity. Drives inflammation and immune cell activation in chronic liver disease.
  • GeneCards: CD40LG
• BST2 (Bone Marrow Stromal Antigen 2 / CD317 / Tetherin): BST2 is an interferon-inducible transmembrane protein known for its antiviral activity, particularly against enveloped viruses. It can also be expressed on various immune cells and modulate immune responses. In the context of chronic liver disease like cirrhosis, which can have viral etiologies or sustained inflammatory stimuli, upregulation of BST2 on CD4+ T cells may reflect ongoing viral defense mechanisms, general inflammatory responses, or specific immunoregulatory functions.
  • Signaling Pathways: Interferon signaling pathways.
  • Biological Mechanism: Antiviral restriction factor, may also modulate immune cell activation and cytokine production.
  • GeneCards: BST2
• SIGIRR (Single Ig and Toll-interleukin 1 Receptor Domain / TIR8): SIGIRR is an inhibitory receptor that negatively regulates Toll-like receptor (TLR) and IL-1 receptor (IL-1R) signaling pathways. By attenuating these pro-inflammatory pathways, SIGIRR plays a role in preventing excessive inflammation and maintaining immune homeostasis. Its upregulation in cirrhotic CD4+ T cells could represent a compensatory mechanism to control the chronic inflammation in the liver, potentially marking a regulatory T cell phenotype or an attempt to limit tissue damage.
  • Signaling Pathways: TLR signaling, IL-1R signaling.
  • Biological Mechanism: Negative regulator of innate immune signaling, dampens inflammation. Its expression suggests an attempt to limit inflammatory responses.
  • GeneCards: SIGIRR
• LMAN2 (Lectin Mannose Binding 2): LMAN2 is typically known as an endoplasmic reticulum (ER)-resident protein involved in protein quality control and glycosylation. Its identification as a "surfaceome marker" is atypical. If truly surface-expressed in cirrhotic CD4+ T cells, it could indicate severe cellular stress, altered protein trafficking, or the shedding of ER-derived vesicles to the cell surface in response to chronic liver injury. This would warrant further investigation to confirm its surface localization and functional relevance in this context.
  • Signaling Pathways: Not directly associated with surface receptor signaling. Potentially related to ER stress pathways.
  • Biological Mechanism: Primarily ER protein, if surface-localized, might indicate cellular stress or novel trafficking mechanisms.
  • UniProt: LMAN2
• HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha Chain): HLA-DRA is a subunit of the HLA-DR molecule, a Class II MHC complex. Class II MHC molecules are crucial for presenting exogenous antigens to CD4+ T cells. While primarily expressed on professional APCs, HLA-DR can be induced on activated T cells, including CD4+ T cells, particularly during inflammation or in certain regulatory T cell subsets. Its elevated expression in cirrhotic CD4+ T cells suggests an enhanced capacity for antigen presentation (e.g., self-antigens in an autoimmune context, or pathogen-derived antigens) or a heightened state of activation that contributes to the ongoing immune response in cirrhosis.
  • Signaling Pathways: Antigen presentation pathway.
  • Biological Mechanism: Presents processed antigens to CD4+ T cells, crucial for initiating and regulating adaptive immune responses. Its upregulation points to activated T cells with potential antigen-presenting functions.
  • GeneCards: HLA-DRA

Overall, the expression profile of these surfaceome markers in cirrhotic CD4+ T cells strongly points towards a highly activated, proliferative, and immunologically engaged population. The co-expression of activatory (IL2RG, CD40LG, HLA-DRA, LY6E) and potentially inhibitory/regulatory (SIT1, SIGIRR) markers suggests a complex and dysregulated immune environment within the cirrhotic liver, where T cells are both contributing to inflammation and possibly attempting to control it.

Clinical or Translational Implications

The differential expression of these surfaceome markers in CD4+ T cells in liver cirrhosis holds significant clinical and translational potential.

1. Biomarkers of Disease Activity/Prognosis: Upregulated markers like CD40LG, IL2RG, and HLA-DRA could serve as diagnostic or prognostic biomarkers for assessing disease activity, progression, or response to therapy in cirrhosis. Monitoring their expression on circulating or liver-resident CD4+ T cells via flow cytometry could provide valuable insights.
2. Therapeutic Targets:
   • CD40LG (CD154): The CD40-CD40L axis is a well-established target in inflammatory and autoimmune diseases. Blocking CD40L could attenuate the inflammatory cascade in cirrhosis by reducing T cell-APC interactions, B cell activation, and downstream cytokine production. Anti-CD40L antibodies have been explored in various immune-mediated conditions. PubMed search: CD40L blockade cirrhosis
   • IL2RG: Modulating IL-2 signaling, particularly via the IL-2 receptor, is a strategy to control T cell proliferation and differentiation. Agents that selectively inhibit or enhance specific IL-2R components could be considered.
   • SIGIRR: As an inhibitory receptor, agonists that enhance SIGIRR function could potentially dampen excessive TLR/IL-1R-mediated inflammation in the cirrhotic liver. This represents a strategy to restore immune homeostasis. PubMed search: SIGIRR anti-inflammatory therapy
   • SIT1: Given its role in negatively regulating TCR signaling, therapies aiming to fine-tune SIT1 activity could potentially modulate T cell hyperactivation, though this requires careful consideration to avoid inducing immunodeficiency.
3. Understanding Disease Pathogenesis: The co-expression of markers associated with activation (CD40LG, HLA-DRA) and potential regulation/exhaustion (SIT1, SIGIRR) suggests a dynamic and complex role for CD4+ T cells in cirrhosis. Further functional studies are warranted to delineate the specific roles of these T cell subsets. Investigating the novel expression of GYPC and LMAN2 (if validated as surfaceome markers) could reveal unexpected cellular stress pathways or adaptive mechanisms in the cirrhotic liver.
4. Experimental Validation: Confirmation of these findings should involve complementary techniques such as multi-parameter flow cytometry or immunohistochemistry to validate the surface expression and cell-type specificity of these markers. Functional assays, *in vitro* and *in vivo*, are crucial to understand the exact contribution of these molecules to CD4+ T cell function and overall disease pathology in cirrhosis, and to test the efficacy of targeting these pathways.

15. Gene Ontology (GSA) Analysis for Cholangiocytes in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GO) enrichment results for Cholangiocytes from single-cell RNA sequencing data. The analysis identifies biological pathways and terms significantly associated with up-regulated genes in Cholangiocytes when comparing two conditions: 'cirrhosis' versus 'healthy' (referred to as 'others' in the plot title, as 'healthy' is the reference condition), and 'healthy' versus 'cirrhosis' (again, 'cirrhosis' is 'others' in this context). The results are visualized as bar plots, displaying the top enriched terms ranked by their statistical significance (-log(p-value) and -log(q-value)). This provides insights into the functional shifts occurring in Cholangiocytes during liver cirrhosis.

Visual Summary

The provided bar plots show the Gene Ontology (GO) terms enriched based on up-regulated differentially expressed genes (DEGs) in Cholangiocytes under two comparative conditions:

1. GSA for Cholangiocyte: cirrhosis_vs_others (Based on up-regulated DEGs): This plot highlights pathways that are significantly up-regulated in Cholangiocytes from individuals with cirrhosis compared to healthy controls.
   • Highly Enriched Terms: The most significantly enriched terms (highest -log(p-val) and -log(q-val)) include "Ribosome", "Parkinson disease", "Huntington disease", "Prion disease", "Amyotrophic lateral sclerosis", "Oxidative phosphorylation", and "Protein processing in endoplasmic reticulum". These terms largely point towards altered protein synthesis and degradation, mitochondrial dysfunction, and cellular stress responses.
   • Infection/Immune Response: Terms like "Salmonella infection", "Staphylococcus aureus infection", "Epstein-Barr virus infection", and "Phagosome" suggest an activation of immune and inflammatory pathways.
2. GSA for Cholangiocyte: healthy_vs_others (Based on up-regulated DEGs): This plot identifies pathways that are significantly up-regulated in Cholangiocytes from healthy individuals compared to those with cirrhosis. These represent pathways that are relatively more active in a healthy state and potentially suppressed or altered in cirrhosis.
   • Highly Enriched Terms: Top terms include "MAPK signaling pathway", "TNF signaling pathway", "Proteoglycans in cancer", "Focal adhesion", "Tight junction", "IL-17 signaling pathway", "Hippo signaling pathway", and "PI3K-Akt signaling pathway". These pathways are crucial for cell communication, structural integrity, growth, and immune modulation.
   • Cellular Structure and Metabolism: Terms like "Focal adhesion" and "Tight junction" emphasize the importance of cell adhesion and barrier function. "mTOR signaling pathway" and "Insulin resistance" indicate metabolic and growth regulation.

Biological Interpretation

The comparison reveals distinct functional profiles for Cholangiocytes in healthy versus cirrhotic livers, indicating significant cellular reprogramming during disease progression.

Cholangiocytes in Cirrhosis Exhibit Cellular Stress and Dysregulation

• The strong enrichment of terms such as "Ribosome", "Proteasome", and "Protein processing in endoplasmic reticulum" suggests a significant burden on the protein synthesis and degradation machinery in cirrhotic cholangiocytes. This can indicate increased protein turnover, accumulation of misfolded proteins, or a compensatory response to cellular stress.
• "Oxidative phosphorylation" enrichment points to altered mitochondrial function and energy metabolism, which is a common hallmark of cellular stress and damage in chronic liver disease.
• The enrichment of pathways associated with "Parkinson disease", "Huntington disease", "Prion disease", and "Amyotrophic lateral sclerosis" is notable. While these are neurodegenerative disorders, the pathways often involve shared cellular mechanisms such as protein aggregation, misfolding, and mitochondrial dysfunction, suggesting that cholangiocytes in cirrhosis are undergoing similar proteotoxic stress responses.
• The activation of "Phagosome" and various infection-related pathways ("Salmonella infection", "Staphylococcus aureus infection", "Epstein-Barr virus infection") highlights the inflammatory microenvironment in cirrhosis and potentially increased immune surveillance or interaction of cholangiocytes with pathogens.

Healthy Cholangiocytes Maintain Structural Integrity and Regulated Signaling

• The prominence of "MAPK signaling pathway", "TNF signaling pathway", "IL-17 signaling pathway", "PI3K-Akt signaling pathway", and "NF-kappa B signaling pathway" in healthy cholangiocytes signifies active and regulated cellular communication, proliferation, and survival mechanisms. These pathways are fundamental for maintaining normal cholangiocyte function and tissue homeostasis.
• "Focal adhesion" and "Tight junction" pathways are critical for cell-cell adhesion and the maintenance of epithelial barrier function. Their relative enrichment in healthy cholangiocytes suggests that these vital structural components are well-maintained in health, but potentially compromised or altered in cirrhosis, contributing to bile duct dysfunction and fibrosis.
• "Hippo signaling pathway" and "mTOR signaling pathway" are key regulators of organ size, proliferation, and cell growth, indicating a tightly controlled growth and regeneration capacity in healthy cholangiocytes.

Clinical or Translational Implications

These findings provide insights into the pathological changes occurring in cholangiocytes during cirrhosis:

• Therapeutic Targets for Cholangiocyte Dysfunction: Pathways related to protein processing, oxidative stress, and proteotoxicity are significantly altered in cirrhotic cholangiocytes. Targeting these stress response pathways could potentially mitigate cholangiocyte injury and dysfunction, thereby slowing the progression of cholestasis and fibrosis in cirrhosis.
• Restoring Homeostasis: The relative downregulation of key signaling, adhesion, and structural integrity pathways in cirrhotic cholangiocytes (as inferred from their enrichment in healthy cells) suggests a loss of normal cholangiocyte function. Strategies aimed at restoring these fundamental cellular processes could be beneficial in maintaining bile duct integrity and function in cirrhotic patients.
• Inflammatory Contribution: The activation of specific immune and infection-related pathways in cirrhotic cholangiocytes underscores their active role in the inflammatory response characteristic of cirrhosis. Modulating these responses might offer avenues to control inflammation-driven liver damage.

16. Gene Set Enrichment Analysis (GSEA) in Liver Cirrhosis

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot. It compares gene set enrichment across different celltype_minor populations in the liver, specifically contrasting the cirrhosis condition against the healthy condition (indicated as cirrhosis_vs_others and healthy_vs_others on the x-axis) based on precomputed gene rankings. The y-axis lists various biological pathways and processes. The color of each dot represents the Normalized Enrichment Score (NES), with red indicating pathways enriched (upregulated) in the test condition (e.g., cirrhosis) and blue indicating pathways depleted (downregulated). The size of each dot corresponds to the statistical significance, specifically the negative logarithm of the p-value (-log(P)), where larger dots signify higher significance. This visualization allows for a comprehensive overview of pathway alterations across diverse cell types in the context of liver cirrhosis.

Visual Summary

The dot plot reveals a complex landscape of pathway alterations across different cell types in liver cirrhosis.

• Overall Pattern: There is a pronounced shift towards upregulation (red dots, positive NES) of inflammatory, immune, fibrogenic, and stress-related pathways in the cirrhosis_vs_others comparisons across many cell types, contrasting with more varied or depleted (blue dots, negative NES) patterns in the healthy_vs_others comparisons for some of these pathways.
• Highly Enriched Pathways in Cirrhosis: Several pathways show strong and significant enrichment (large red dots) across multiple cell types in cirrhosis. These include:
  • Immune and Inflammatory Responses: Cytokine-cytokine receptor interaction, Chemokine signaling pathway, NF-kappa B signaling pathway, Antigen processing and presentation, and IL-17 signaling pathway are highly enriched in immune cells (Macrophages, T cells, Dendritic cells) and also in non-parenchymal cells (Hepatic stellate cells, Endothelial cells, Cholangiocytes, Smooth muscle cells). Complement and coagulation cascades are also notable.
  • Fibrosis and ECM Remodeling: ECM-receptor interaction and Focal adhesion pathways are particularly enriched in Hepatic stellate cells, Endothelial cells, Cholangiocytes, and Smooth muscle cells, key players in liver fibrosis.
  • Cell Stress and Death: Protein processing in endoplasmic reticulum (ER stress), Apoptosis, Necroptosis, and Ferroptosis show significant enrichment across various cell types, indicating widespread cellular stress and programmed cell death.
  • Metabolic Dysregulation and Disease Context: Non-alcoholic fatty liver disease, Lipid and atherosclerosis, and Pathways in cancer are broadly enriched, reflecting the metabolic complexities and increased cancer risk associated with cirrhosis. Pathways related to Hepatitis B and Hepatitis C infections are also notably enriched in several cell types, consistent with common etiologies of cirrhosis.
• Depleted Pathways in Cirrhosis: In contrast, Oxidative phosphorylation, AMPK signaling pathway, and Glycolysis / Gluconeogenesis pathways show depletion (blue dots, negative NES) in immune cells such as Macrophages and T cells (CD4+ and CD8+) in the cirrhosis condition, suggesting metabolic reprogramming or impaired energy metabolism in these immune populations. Interestingly, Oxidative phosphorylation and Glycolysis / Gluconeogenesis are enriched in other cell types like Cholangiocytes and Hepatic stellate cells, highlighting cell-type specific metabolic adaptations.
• Cell Type Specificity: The plot clearly delineates differential pathway activation across cell types. For example, Hepatic stellate cells and Macrophages appear to be central hubs for numerous pro-fibrotic, inflammatory, and metabolic alterations. T cells and B cells also exhibit strong immune activation profiles.

Biological Interpretation

The GSEA results provide profound insights into the underlying biological processes driving liver cirrhosis.

1. Pervasive Inflammation and Immune Activation: The robust enrichment of pathways such as Cytokine-cytokine receptor interaction, Chemokine signaling pathway, NF-kappa B signaling pathway, and IL-17 signaling pathway across almost all examined cell types in cirrhosis underscores a state of chronic, widespread inflammation. Macrophages, T cells, and even non-immune cells like Hepatic stellate cells and Endothelial cells are actively involved in this inflammatory cascade. This sustained inflammation is a hallmark of progressive liver disease and fuels fibrosis. The enrichment of Antigen processing and presentation suggests enhanced immune surveillance and activation, potentially driven by persistent injury or pathogen exposure.
2. Fibrogenesis and Extracellular Matrix (ECM) Remodeling: The prominent activation of ECM-receptor interaction and Focal adhesion pathways, particularly in Hepatic stellate cells, Endothelial cells, and Smooth muscle cells, is a direct signature of liver fibrosis. Hepatic stellate cells are the primary fibrogenic cells in the liver, and their activation, marked by these pathways, leads to excessive production and deposition of ECM components, a defining feature of cirrhosis. Endothelial and smooth muscle cells also contribute to the architectural distortion of the cirrhotic liver.
3. Metabolic Reprogramming and Cellular Stress:
   • Immune Cell Metabolic Shift: The downregulation of Oxidative phosphorylation, AMPK signaling pathway, and Glycolysis / Gluconeogenesis in macrophages and T cells during cirrhosis suggests a metabolic switch. Activated immune cells often undergo metabolic reprogramming (e.g., shifting from oxidative phosphorylation to glycolysis) to meet energy demands for proliferation and effector functions. The observed downregulation of oxidative phosphorylation might indicate a state of metabolic exhaustion or a preference for alternative, less efficient metabolic routes in these immune cells, which is a known feature in chronic inflammatory conditions and cancer.
   • HSC and Cholangiocyte Metabolic Adaptations: Conversely, the upregulation of Glycolysis / Gluconeogenesis, Pyruvate metabolism, Fatty acid degradation, and Non-alcoholic fatty liver disease in Hepatic stellate cells and Cholangiocytes highlights their metabolic adaptations in the cirrhotic environment. These cells might be utilizing alternative energy sources or undergoing specific metabolic reprogramming that contributes to their activated, pro-fibrotic phenotypes. The link to NAFLD pathways is particularly relevant given its increasing prevalence as a cause of cirrhosis.
   • Endoplasmic Reticulum Stress and Cell Death: The enrichment of Protein processing in endoplasmic reticulum signifies ER stress, a cellular response to misfolded proteins that can arise from chronic injury or metabolic imbalances. Coupled with the widespread activation of Apoptosis, Necroptosis, and Ferroptosis pathways, this points to significant cellular damage, turnover, and different forms of regulated cell death occurring in the cirrhotic liver, contributing to tissue destruction and inflammation.
4. Etiological and Oncogenic Links: The enrichment of Hepatitis B and Hepatitis C infection pathways in multiple cell types directly links these viral etiologies to the development of cirrhosis. The consistent activation of Pathways in cancer across various cell types, especially Hepatic stellate cells and Cholangiocytes, underscores the heightened risk of hepatocellular carcinoma (HCC) in individuals with cirrhosis.

Clinical or Translational Implications

The findings from this GSEA analysis have several important clinical and translational implications for liver cirrhosis:

• Diagnostic and Prognostic Biomarkers: Pathways consistently altered across multiple cell types, such as Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, ECM-receptor interaction, and specific cell death pathways (e.g., Ferroptosis), could yield novel diagnostic or prognostic biomarkers for cirrhosis progression and severity. Circulating markers reflecting these pathways could be non-invasive indicators of disease activity.
• Therapeutic Targets: The identified key pathways, particularly NF-kappa B signaling, IL-17 signaling, and components of ECM-receptor interaction or Focal adhesion, represent potential therapeutic targets. Modulating these pathways could attenuate inflammation and fibrosis. For example, targeting specific cytokines or their receptors could dampen the inflammatory milieu, while inhibiting HSC activation pathways could halt fibrosis progression.
• Understanding Metabolic Vulnerabilities: The differential metabolic reprogramming observed in immune cells versus fibrogenic cells suggests opportunities for cell-type specific metabolic interventions. For instance, strategies to restore normal oxidative phosphorylation in immune cells or to disrupt maladaptive metabolic pathways in HSCs could be explored.
• HCC Surveillance and Prevention: The strong link to Pathways in cancer emphasizes the critical need for continued HCC surveillance in cirrhotic patients and highlights potential molecular targets for chemoprevention strategies. Understanding which cell types activate these oncogenic pathways in early cirrhosis could inform risk stratification.
• Etiology-Specific Interventions: The presence of Hepatitis B/C pathways underscores the importance of antiviral therapies in preventing or reversing cirrhosis progression in affected individuals.

This comprehensive pathway analysis provides a foundation for understanding the intricate molecular and cellular mechanisms in liver cirrhosis, opening avenues for developing more effective diagnostics and targeted therapies.

17. Discussion

This comprehensive single-cell analysis of human liver tissue provides a detailed landscape of cellular and molecular alterations in cirrhosis compared to healthy controls, revealing multifaceted pathological processes.

Profound Cellular Remodeling and Fibrogenesis: The most striking finding is the dramatic cellular remodeling. Cirrhotic livers exhibit a significant reduction in hepatocytes, the functional cells of the liver, coupled with a marked expansion of fibrogenic cells such as Hepatic Stellate Cells (HSCs), Fibroblasts, Cholangiocytes, and Endothelial cells. This shift is a hallmark of fibrosis, the central pathological process in cirrhosis. HSCs, identified by markers like ENG, ITGA1, and CD44, are heavily activated in cirrhosis, driving extracellular matrix (ECM) deposition. Cholangiocytes also show distinct changes, upregulating markers like EFNA1, ERBB3/ERBB2, and ABCC3, and exhibiting increased protein processing and oxidative stress pathways, indicating their active role in biliary hyperplasia and a stressed state. Cell-cell interaction analysis further underscores the central role of fibrogenesis, with extensive integrin-mediated interactions (e.g., SPP1-integrin, FN1-integrin, Collagen-integrin) prominently activated in cirrhosis, primarily involving HSCs, Endothelial cells, and various immune cells.

Dysregulated Immune Microenvironment: Cirrhosis is characterized by a highly active and dysregulated immune response. Macrophages display a significant shift towards a pro-inflammatory M1 phenotype, with increased proportions of Mac (M1) and decreased Mac (M2A) in cirrhosis. These cirrhotic macrophages upregulate markers like FCGR1A/FCGR2A (Fc-gamma receptors), CD33, and BSG (CD147), indicating enhanced immune activation and involvement in ECM remodeling. T cell populations are also dramatically altered; there is an expansion of regulatory (Treg) and pro-inflammatory helper T cell subsets (Th17, Th22, Th1, LTI), accompanied by a significant contraction of cytotoxic T cells (T_Cyto) and naive T cells (T_Naive). This suggests an immunosuppressive microenvironment alongside chronic inflammation, potentially compromising antiviral/antitumor immunity and exacerbating tissue damage. Notably, Innate Lymphoid Cells (ILC1 and ILC2), crucial for tissue protection and repair, are severely depleted in cirrhosis. Cell-cell interaction data highlights widespread immune cell crosstalk, including the prominent CXCL12-CXCR4 axis involving HSCs and T cells, and inflammatory lipid mediators, indicating persistent immune cell recruitment and activation. CD4+ T cells in cirrhosis show an activated phenotype, upregulating markers like CD40LG, IL2RG, and HLA-DRA, while also showing markers (SIT1, SIGIRR) that might indicate attempts at immune regulation or exhaustion.

Metabolic Reprogramming and Cellular Stress: GSEA reveals broad metabolic reprogramming and cellular stress. While macrophages and T cells show depletion of oxidative phosphorylation and glycolysis, fibrogenic cells like HSCs and Cholangiocytes exhibit enrichment in glycolysis, pyruvate metabolism, and fatty acid degradation. This cell-type specific metabolic adaptation likely fuels their activated and pro-fibrotic phenotypes. Widespread endoplasmic reticulum stress (Protein processing in endoplasmic reticulum) and various cell death pathways (apoptosis, necroptosis, ferroptosis) are also significantly enriched across multiple cell types, pointing to chronic cellular damage and turnover. Furthermore, the strong enrichment of Non-alcoholic fatty liver disease, Hepatitis B, Hepatitis C, and Pathways in cancer directly links these etiological factors and comorbidities to the observed cellular pathologies, underscoring the heightened risk of hepatocellular carcinoma in cirrhotic patients.

In summary, liver cirrhosis is characterized by a pathological interplay between injured parenchymal cells, activated fibrogenic cells, and a dysregulated immune system. This study provides a detailed, cell-type-specific understanding of the molecular mechanisms driving these changes, offering a robust foundation for identifying novel biomarkers and therapeutic targets.

Hypotheses:

1. Chronic inflammation driven by M1-polarized macrophages and specific T cell subsets (Th1, Th17, Th22, Treg) directly contributes to hepatocyte injury and activation of fibrogenic cells in cirrhosis.
2. The depletion of tissue-protective Innate Lymphoid Cells (ILC1/ILC2) in cirrhotic livers impairs tissue repair and immune surveillance, exacerbating disease progression and increasing susceptibility to complications.
3. Enhanced integrin-mediated cell-extracellular matrix interactions, particularly involving Hepatic Stellate Cells and Endothelial cells, are central to the persistent activation of fibrogenic pathways and architectural distortion in cirrhosis.
4. Cholangiocytes undergo a pro-fibrotic and stress-response reprogramming, characterized by upregulation of ERBB signaling and metabolic dysfunction, contributing to biliary hyperplasia and the progression of cholestatic fibrosis.
5. Dysregulated iron metabolism, indicated by reduced SLC40A1 (Ferroportin-1) in macrophages, contributes to oxidative stress and exacerbates liver damage and inflammation in cirrhosis.

Potential therapeutic targets:

1. Endoglin (ENG/CD105): ENG is a crucial co-receptor for TGF-β signaling and a regulator of angiogenesis, both central to liver fibrosis. Its significant upregulation in cirrhotic Hepatic Stellate Cells (HSCs) enhances pro-fibrotic responses and pathological angiogenesis. Evidence: Upregulated in cirrhotic HSCs (Section 13). Involved in TGF-β signaling and angiogenesis. GSEA shows enrichment of 'ECM-receptor interaction' and 'Focal adhesion' pathways in HSCs in cirrhosis (Section 16). Validation: Evaluate the efficacy of monoclonal antibodies (e.g., TRC105) or small molecule inhibitors targeting ENG in *in vitro* HSC activation assays and *in vivo* liver fibrosis models to assess reduction in ECM production, HSC proliferation, and portal hypertension.
2. Integrin Alpha 1 (ITGA1/CD49a): ITGA1, forming Integrin VLA-1, is a collagen/laminin receptor highly upregulated in cirrhotic Hepatic Stellate Cells. It is essential for HSC adhesion to the fibrotic extracellular matrix, promoting their survival and sustained activation in the diseased liver. Evidence: Highly upregulated in cirrhotic HSCs (Section 13). Integrin-mediated interactions are extensively activated in cirrhosis, involving ECM components (Section 10). GSEA shows 'ECM-receptor interaction' and 'Focal adhesion' pathway enrichment in HSCs (Section 16). Validation: Develop or repurpose specific ITGA1 inhibitors to disrupt HSC-ECM interactions in *in vitro* 3D cultures and *in vivo* liver fibrosis models, evaluating their impact on HSC activation, apoptosis, and overall fibrosis resolution.
3. CXCL12-CXCR4 Axis: The CXCL12-CXCR4 axis is a prominent cell-cell interaction in cirrhosis, involving Hepatic Stellate Cells and T cells. It drives the recruitment of immune cells and HSCs to the liver, exacerbating inflammation and fibrogenesis. Evidence: Strong CXCL12-CXCR4 interaction observed in cirrhotic cell-cell interaction analysis (Section 10). GSEA shows 'Chemokine signaling pathway' enrichment in HSCs and T cells in cirrhosis (Section 16). Validation: Test CXCR4 antagonists (e.g., Plerixafor) in preclinical liver fibrosis models to assess their ability to reduce immune cell infiltration, HSC activation, and progression of fibrosis.
4. CD40 Ligand (CD40LG/CD154): CD40LG is highly upregulated on activated CD4+ T cells in cirrhosis. It forms a critical costimulatory axis (CD40-CD40L) that drives B cell activation and robust adaptive immune responses, significantly contributing to chronic inflammation in the liver. Evidence: Upregulated on cirrhotic CD4+ T cells (Section 14). GSEA shows 'Cytokine-cytokine receptor interaction', 'NF-kappa B signaling pathway', and 'Antigen processing and presentation' enrichment in T cells in cirrhosis (Section 16). Validation: Utilize anti-CD40L antibodies in *in vitro* T cell-APC co-cultures and *in vivo* cirrhosis models to evaluate reductions in T cell activation, B cell responses, cytokine production, and amelioration of liver inflammation and fibrosis.
5. Extracellular Matrix Metalloproteinase Inducer (BSG/CD147): BSG (CD147) is significantly upregulated on cirrhotic macrophages. It stimulates the production of matrix metalloproteinases (MMPs), thereby promoting aberrant extracellular matrix remodeling, inflammation, and angiogenesis, all key features of cirrhosis. Evidence: Upregulated on cirrhotic macrophages (Section 12). Cell-cell interaction analysis indicates widespread ECM remodeling (Sections 9, 10). GSEA shows 'ECM-receptor interaction' and 'Focal adhesion' enrichment across multiple cell types in cirrhosis (Section 16). Validation: Test anti-CD147 antibodies or MMP inhibitors in macrophage cultures to assess reductions in MMP secretion and pro-fibrotic cytokine production. Validate *in vivo* in liver fibrosis models to measure impacts on ECM deposition and inflammation.
6. ERBB3/ERBB2 (HER3/HER2): ERBB3 and ERBB2 are receptor tyrosine kinases significantly upregulated in cirrhotic Cholangiocytes. They drive pathogenic cholangiocyte proliferation (biliary hyperplasia) and contribute to fibrogenesis via activation of PI3K/Akt/mTOR and Ras/MAPK signaling pathways. Evidence: Upregulated in cirrhotic Cholangiocytes (Section 11). GSA for healthy cholangiocytes shows enrichment in 'MAPK signaling pathway', 'PI3K-Akt signaling pathway', and 'mTOR signaling pathway' (Section 15), implying dysregulation in cirrhosis. GSEA shows 'Pathways in cancer' enrichment across various cell types in cirrhosis (Section 16), consistent with oncogenic signaling. Validation: Repurpose ERBB tyrosine kinase inhibitors or monoclonal antibodies (e.g., Trastuzumab, Lapatinib) to inhibit cholangiocyte proliferation and fibrotic responses in *in vitro* cholangiocyte cultures and *in vivo* cholestatic liver injury/fibrosis models.

Follow-up validation ideas:

1. Flow Cytometry & Immunohistochemistry: Validate changes in T cell (Treg, Th17, Th22, T_Cyto) and macrophage (M1, M2A) subset proportions and their activation markers (e.g., CD40LG, HLA-DRA, FCGR1A, BSG) using multi-parameter flow cytometry. Use immunohistochemistry or spatial transcriptomics to confirm the localization and spatial relationships of these cell types and their surface markers within cirrhotic liver tissue.
2. In Vitro Perturbation Assays: Test the functional impact of targeting key surface markers (e.g., ENG, ITGA1 on HSCs; CD40LG on T cells; FCGRs, BSG on macrophages; EFNA1, ERBBs on cholangiocytes) using specific inhibitors or genetic knockdowns/overs in isolated liver cell lines or primary cells (HSCs, macrophages, cholangiocytes) to assess effects on proliferation, activation, cytokine production, and ECM synthesis.
3. In Vivo Disease Models: Employ animal models of liver cirrhosis (e.g., CCl4-induced, NASH models) to validate the therapeutic potential of targeting identified pathways (e.g., CXCR4, integrins, ERBBs, CD147) using pharmacological agents or gene therapy, evaluating changes in fibrosis markers, inflammation, and liver function.
4. Spatial Transcriptomics / Ligand-Receptor Blockade: Further delineate the roles of specific cell-cell interactions (e.g., CXCL12-CXCR4, SPP1-integrin, HLA-G-LILRB) by performing *in situ* proximity ligation assays or *in vitro* co-culture experiments with specific ligand/receptor blocking agents to assess their impact on cell activation and fibrogenic output.
5. Biomarker Validation in Cohorts: Assess the prognostic or diagnostic value of key surfaceome markers (e.g., ENG, CD44, FCGR1A, CD40LG) identified in liver tissue by evaluating their levels in peripheral blood or liver biopsies from independent cohorts of patients with varying stages of cirrhosis using techniques like ELISA, proteomics, or single-cell sequencing.

Limitations:

The inference of 'Cirrhosis' as the disease context is based on dataset metadata, not direct clinical diagnosis, and should be considered provisional. Single-cell RNA sequencing provides correlative data, and while it strongly indicates molecular and cellular changes, direct causality requires dedicated functional validation experiments. The current analysis is observational rather than interventional. While the sample size is adequate for differential analysis, it might not fully capture the complete spectrum of rare cell states or the full heterogeneity of disease presentation in cirrhosis. All findings warrant further independent experimental validation.

18. Query List

1. Show and save UMAPs for condition, sample, major cell type, minor cell type, and celltype_subset in two columns.
2. Show major cell type scores on UMAP and save the result.
3. Show and save a marker expression dot plot for celltype_subset. Set target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
4. Show and save a population bar plot of minor cell types.
5. Show and save a population bar plot of T cell subsets.
6. Show and save box plots of T cell subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
7. Show and save a population bar plot of macrophage subsets.
8. Show and save box plots of macrophage subset populations with statistically significant differences between conditions, if any. Choose ncols based on the total number of panels.
9. Show and save cell-cell interaction patterns. Select at most 80 cell-cell interactions per group.
10. Find cell-cell interactions involving major tissue cells, immune cells and stromal cells that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context for Liver tissue and Cirrhosis disease, describe the associated signaling pathways and mechanisms and, where relevant, its potential as a therapeutic target and related therapeutic agents.
11. Show marker expressions for Cholangiocytes in a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition. For each marker identified under each condition, using the provided dataset context for Liver tissue and Cirrhosis disease, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for the disease and related therapeutic agents.
12. Show marker expressions for Macrophage in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context for Liver tissue and Cirrhosis disease, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for the disease and related therapeutic agents.
13. Show marker expressions for Hepatic stellate cell in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context for Liver tissue and Cirrhosis disease, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for the disease and related therapeutic agents.
14. Show marker expressions for T cell CD4+ in a dot plot, and save the result. Use only surfaceome markers, with at most 40 markers per condition. For each marker identified under each condition, using the provided dataset context for Liver tissue and Cirrhosis disease, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for the disease and related therapeutic agents.
15. Show Gene Ontology (GSA) analysis results for Cholangiocytes as a bar plot, and save the result.
16. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.